raloxifene hydrochloride has been researched along with Osteoporosis in 333 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 23 (6.91) | 18.2507 |
| 2000's | 194 (58.26) | 29.6817 |
| 2010's | 100 (30.03) | 24.3611 |
| 2020's | 16 (4.80) | 2.80 |
| Authors | Studies |
|---|---|
| Baim, S; Bedrose, S; Casagrande, A; Go, MT; Goel, M; Hanna, M; Husni, H; Li, D; Mahrous, P; Morkos, M | 1 |
| Chen, CH; Chen, WJ; Chen, YM; Chien, LN; Ku, CK; Li, CY; Lin, SY | 1 |
| Fukunaga, M; Hagino, H; Mori, S; Nakamura, T; Ohta, H; Orimo, H; Shiraki, M; Soen, S; Sone, T; Tanaka, S; Uemura, Y | 1 |
| Jenal, M; Ma, N; Moshi, MR; Nicolopoulos, K; Stringer, D; Vreugdenburg, T | 1 |
| Fass, R; Hill, H; Liu, BD; Saleh, S; Song, G; Udemba, SC | 1 |
| Elgebaly, Z; Elliott, J; Naik-Panvelkar, P; Norman, S; Pollack, A; Seibel, MJ; Thistlethwaite, J; Weston, C | 1 |
| Brito, VGB; Castoldi, RC; Chaves-Neto, AH; Ciarlini, PC; Dornelles, RCM; Ervolino, E; Fernandes, F; Louzada, MJQ; Menezes, AP; Nicola, ÂC; Oliveira, SHP; Peres-Ueno, MJ; Stringhetta-Garcia, CT | 1 |
| Ahmed, OA; Alfaleh, MA; Alhakamy, NA; Bahmdan, RH; Elkomy, MH; Hosny, KM | 1 |
| Bauer, DC; Clarke, BL; Drake, MT; Tsourdi, E; Yu, EW | 1 |
| Duke, J; Hripcsak, G; Huser, V; Jin, P; Kim, Y; Lambert, CG; Madigan, D; Park, H; Park, RW; Reich, C; Rijnbeek, PR; Ryan, PB; Schuemie, MJ; Shah, NH; Suchard, MA; Tian, Y; Van Zandt, M; Vashisht, R; Wu, Y; Yang, J; You, SC | 1 |
| Gong, L; Qian, HJ; Tan, MS; Yang, N; Zhang, LK; Zhang, YY | 1 |
| Chen, D; Huang, X; Jin, Z; Liu, Q; Ma, T; Ye, Z | 1 |
| Lian, QQ; Liu, H; Ping, SH; Shao, LT; Sun, Q; Tian, FM; Zhang, L | 1 |
| Hagino, H; Mori, S; Nakamura, T; Ohta, H; Sone, T; Uemura, Y | 1 |
| Kosiorowska, J; Szymańska-Chabowska, A; Tański, W | 1 |
| Liu, F; Nan, XY; Ping, SH; Sun, Q; Tian, FM; Zhang, L; Zhou, Z | 1 |
| Faverani, LP; Freire, AR; Gruber, R; Hassumi, JS; Luvizuto, ER; Momesso, GAC; Okamoto, R; Polo, TOB; Prado, FB; Ramalho-Ferreira, G; Rossi, AC | 1 |
| Chu, Y; Gayleard, J; Jirru, E; Liu, MC; Rebholz, CM; Robinson, KA; Wilson, LM; Zhang, A | 1 |
| Barry, MJ; Cooke, M; Denberg, TD; Fitterman, N; Forciea, MA; Harris, RP; Humphrey, LL; Kansagara, D; McLean, RM; Mir, TP; Qaseem, A; Schünemann, HJ | 1 |
| Bannuru, RR; Buckley, L; Cannon, M; Fink, HA; Grossman, J; Guyatt, G; Hansen, KE; Humphrey, MB; Lane, NE; Magrey, M; McAlindon, T; Miller, AS; Miller, M; Morrison, L; Osani, M; Rao, M; Robinson, AB; Saha, S; Turgunbaev, M; Vaysbrot, E; Wolver, S | 1 |
| Allen, MR; Alvarez, MB; Bidwell, JP; Burr, DB; Childress, P; Condon, KW; Davis, H; He, Y; Hernandez-Buquer, S; Plotkin, LI; Robling, AG; Shao, Y; Stayrook, KR; Warden, SJ; Wek, RC; Yang, FC | 1 |
| Allen, MR; Aref, M; Brown, DM; Burr, DB; Hammond, M; Hutchins, GD; Jang, T; Jiang, L; Lin, C; McCarthy, BP; McGowan, B; McNerny, E; Newman, CL; Organ, JM; Persohn, S; Riley, AA; Territo, PR; Wallace, JM | 1 |
| Almeida, RP; Chaves-Neto, AH; Dornelles, RCM; Ervolino, E; Fernandes, F; Louzada, MJQ; Morais, SRL; Perez-Ueno, MJ; Stringhetta-Garcia, CT | 1 |
| Dayyani, L; Minaiyan, M; Varshosaz, J | 1 |
| Cerqueira, JMM; Pontes, HAR; Souza, LL; Uchôa, DCC | 1 |
| Jahanian-Najafabadi, A; Minaiyan, M; Sayed-Tabatabaei, L; Varshosaz, J; Ziaei, V | 1 |
| Collister, D; Connelly, K; Tangri, N | 1 |
| Chien, JY; Chiu, WY; Lee, JJ; Tsai, KS; Yang, WS | 1 |
| Faverani, LP; Freire, AR; Hassumi, JS; Momesso, GAC; Okamoto, R; Polo, TOB; Prado, FB; Ramalho-Ferreira, G; Rossi, AC; Yogui, FC | 1 |
| Kawasaki, N; Nagai, N; Nakazawa, Y; Ogata, F; Otake, H | 1 |
| Adamkovicova, M; Babosova, R; Galbavy, D; Grosskopf, B; Lukacova, M; Martiniakova, M; Mondockova, V; Omelka, R | 1 |
| Barron, R; Berry, SD; Dufour, AB; Recknor, C; Samelson, EJ; Travison, TG; Yehoshua, A; Zhu, H | 1 |
| Baggott, JE; Morgan, SL | 1 |
| Rajput, SJ; Shah, P | 1 |
| Bi, DD; Guo, YF; Han, MH; Hao, T; Liu, H; Qi, XY; Wang, XG; Wang, XT; Zhang, BX | 1 |
| Imai, T; Nakamura, T; Ohta, H; Orimo, H; Shiraki, M; Soen, S; Sugimoto, T; Taguchi, A; Tanaka, S; Uemura, Y | 1 |
| Cheng, MH; Lee, FK; Lee, WL; Tarng, DC; Wang, PH; Yang, WC | 1 |
| Chen, SH; Cheng, TT; Hsu, CY; Su, BY; Yang, TS; Yu, SF | 1 |
| Allen, MR; Aref, M; Brown, DM; Burr, DB; Gallant, MA; Newman, CL; Organ, JM; Wallace, JM | 1 |
| Ancona, E; Berretta, R; Bertocco, A; Capobianco, G; D'Antona, D; Di Gangi, S; Gizzo, S; Nardelli, GB; Noventa, M; Patrelli, TS; Saccardi, C; Vacilotto, A | 1 |
| Fung, KP; Hung, LK; Ko, CH; Lau, CB; Lau, CP; Leung, PC; Siu, WS | 1 |
| Gandhi, S; Modi, A; Sen, S; Siris, ES; Tang, J | 1 |
| Pinkerton, JV; Thomas, S | 1 |
| Kao Yang, YH; Lin, SJ; Lin, TC; Yang, CY | 1 |
| Ohashi, S; Ono, K; Tanaka, S | 1 |
| Lee, CH; Lin, SJ; Lin, TC; Yang, CY; Yang, YH | 1 |
| Amugongo, SK; Dai, W; Dave, NK; Jia, J; Jiang, L; Lane, NE; Lay, YA; Li, CS; Olivera, D; Panganiban, B; Ritchie, RO; Walsh, D; Yao, W | 1 |
| Chien, JY; Chiu, WY; Juang, JM; Lee, JJ; Tsai, KS; Yang, WS | 1 |
| Lušin, TT; Marc, J; Mrhar, A; Ostanek, B; Pfeifer, M; Trontelj, J; Zavratnik, A; Zegura, B | 1 |
| Felder, M; Ferrari, S; Krieg, MA; Lamy, O; Meier, C; Mellinghoff, HU; Rizzoli, R | 1 |
| Bouvet, A; Caruba, T; Pouchot, J; Sabatier, B; Savoldelli, V | 1 |
| Chhabra, H; Mumtaz, M; Songpatanasilp, T; Sorsaburu, S; Yu, M | 1 |
| Alam, J; Burge, R; Gold, DT; Naegeli, AN; Shen, W; Shih, J; Silverman, S | 1 |
| Beaudart, C; Bruyere, O; Dardenne, N; Emonts, P; Neuprez, A; Reginster, JY | 1 |
| Reid, IR | 1 |
| Faverani, LP; Garcia, IR; Okamoto, R; Prado, FB; Ramalho-Ferreira, G | 1 |
| Faverani, LP; Grossi-Oliveira, GA; Okamoto, R; Okamoto, T; Ramalho-Ferreira, G | 1 |
| Choi, NK; Kim, J; Lee, J; Park, BJ; Shin, JY; Song, HJ | 1 |
| Komm, BS; Pickar, JH | 1 |
| Abrahamsen, B; Hoff, M; Langhammer, A; Meyer, HE; Schei, B; Skurtveit, S; Syversen, U; Søgaard, AJ | 1 |
| Choma, TJ; Harrop, JS; Lubelski, D; Mroz, TE; Steinmetz, MP | 1 |
| Compston, J | 1 |
| Inoue, S; Kuroda, T; Shiraki, M; Tanaka, S; Uenishi, K; Urano, T | 1 |
| Ott, SM | 1 |
| Khan, MM | 1 |
| Fan, CP; Li, Z; Mellström, D; Modi, A; Sajjan, S; Salomonsson, S; Waern, E; Yang, X | 1 |
| Isaka, Y; Sato, M; Sugihara, T; Ye, W | 1 |
| Kobayashi, T; Matsumoto, M; Miyamoto, K; Miyamoto, T; Morita, M; Nakamura, M; Oike, T; Sato, Y; Tando, T; Watanabe, R | 1 |
| Calignano, A; Corrado, B; Lama, A; Mattace Raso, G; Meli, R; Paciello, O; Pagano, TB; Pirozzi, C; Russo, S; Santoro, A | 1 |
| Nakatoh, S | 1 |
| Ohta, H | 7 |
| Mershon, JL; Schoenfeld, MJ; Stock, JL | 1 |
| Masaki, H; Miki, T | 1 |
| McDermott, MT; Minne, P; Vondracek, SF | 1 |
| Altavilla, D; Antoci, S; Armbruster, MA; Bitto, A; Burnett, BP; Di Stefano, V; Granese, R; Irrera, N; Levy, RM; Marini, H; Minutoli, L; Polito, F; Squadrito, F | 1 |
| Laroche, M | 1 |
| Pepersack, T | 1 |
| Cosman, F | 2 |
| Verhaar, HJ | 1 |
| Frosch, KH; Rack, T; Sehmisch, S; Seidlova-Wuttke, D; Stuermer, EK; Stuermer, KM; Tezval, M; Wenda, E; Wuttke, W | 1 |
| Vogel, VG | 1 |
| Boekhoff, J; Herrmann, TR; Rack, T; Sehmisch, S; Seidlova-Wuttke, D; Stuermer, EK; Stuermer, KM; Tezval, H; Tezval, M; Wuttke, W | 1 |
| Lipkovich, I; Qu, Y | 1 |
| Baytur, Y; Demir, BC; Gumuser, G; Inceboz, U; Ozbilgin, K; Uyar, Y | 1 |
| Brookhart, MA; Patrick, A; Solomon, DH | 1 |
| Oshima, H; Tanaka, I | 1 |
| Ito, M | 1 |
| Inaba, M; Shidara, K | 1 |
| Kishimoto, H | 1 |
| Hayashi, Y | 2 |
| Alexander, IM | 1 |
| Kida, Y; Marumo, K; Saito, M; Shinohara, A; Soshi, S; Ushiku, C | 1 |
| Blond, B | 1 |
| Azuma, K | 1 |
| Rawlins, S | 1 |
| Harris, ST; Mitchner, NA | 1 |
| Mosekilde, L; Pinholt, EM; Rejnmark, L; Schwartz, K; Vestergaard, P | 4 |
| Krege, JH; Sontag, A; Wan, X | 1 |
| Araki, Y; Ichikawa, S; Itoh, T; Iwasaki, T; Kanai, H; Kanda, T; Kasama, S; Koizumi, A; Kumakura, H; Kurabayashi, M; Murakami, M; Saito, Y; Sakamaki, T; Sakamoto, H; Sawada, Y; Sumino, H; Takahashi, T; Takayama, Y | 1 |
| Blackwell, T; Cummings, SR; Ensrud, KE; Ishani, A; Slinin, Y | 1 |
| Saito, M | 2 |
| Shimada, H; Takami, M | 1 |
| Hamano, T | 1 |
| Duncan, EL; Gunanti, I; Hollingworth, SA; Nissen, LM | 1 |
| Dillon, ML; Frazee, LA | 1 |
| Beck, TJ; Iba, K; Imanishi, Y; Miki, T; Naka, H; Nakatsuka, K; Takada, J; Wada, H; Yamashita, T; Yoshizaki, T | 1 |
| Frassetto, LA; Gordon, PL | 1 |
| Endo, I; Matsumoto, T | 1 |
| Kawate, H; Takayanagi, R | 1 |
| Brixen, KT; Langdahl, BL; Nielsen, DS; Sørensen, HA; Sørensen, OH | 1 |
| Li, W; Qu, Y | 1 |
| Marc, J; Pfeifer, M; Prezelj, J; Zavratnik, A; Zegura, B | 1 |
| Burr, DB; Diab, T; Guldberg, RE; Reinwald, S; Wang, J | 1 |
| Berthelot, JM; Glémarec, J; Guillot, P; Le Goff, B; Maugars, Y | 1 |
| Mosekilde, L; Rejnmark, L; Schwartz, F; Vestergaard, P | 1 |
| Clarke, BL; Khosla, S | 1 |
| Hayashi, T; Ina, K; Maeda, M; Nomura, H | 1 |
| Mori, S | 1 |
| Altunay, H; Bilgili, H; Gecit, MR; Keskin, D; Tasci, AG | 1 |
| Andersson, A; Carlsten, H; Islander, U; Jochems, C; Lagerquist, MK; Ohlsson, C; Stubelius, A | 1 |
| Landfeldt, E; Lang, A; Robbins, S; Ström, O | 1 |
| Iba, K; Takada, J; Yamashita, T | 1 |
| Hsieh, CF; Huang, WF; Lu, PY; Tsai, YW | 1 |
| Furuya, T | 1 |
| Vestergaard, P | 1 |
| Kinoshita, I; Kojima, E; Matsumura, M; Miura, A; Tajima, T; Tashiro, K; Yoshizawa, A | 1 |
| Karwowski, W; Myśliwiec, M; Naumnik, B; Szczepański, M | 1 |
| Suzuki, H; Takeuchi, Y | 1 |
| Hongo, M; Kasukawa, Y; Miyakoshi, N; Sasaki, S; Shimada, Y | 1 |
| Freedman, AN; McNeel, TS; Stevens, WM; Waters, EA | 1 |
| Berginc, K; Delić, K; Kristl, A; Kullak-Ublick, GA; Marc, J; Mrhar, A; Ostanek, B; Stieger, B; Trdan Lušin, T; Trontelj, J; Zavratnik, A | 1 |
| El-Abd, EE; El-Ashmawy, NE; El-Bahrawy, HA; Haggag, AA; Khedr, NF | 1 |
| Baker, SP; Boskey, AL; Brooks, DJ; Burket, JC; MacLeay, JM; van der Meulen, MC | 1 |
| Carey, EJ; Yadav, A | 1 |
| Briongos, L; Dueñas-Laita, A; García-Alonso, M; Pérez-Castrillón, JL; Ruiz-Mambrilla, M; Sañudo, S | 1 |
| Jordan, VC; Pappas, SG | 1 |
| Blackwell, T; Gilchrist, N; March, R; Shand, B | 1 |
| Minne, HW; Pfeifer, M; Pollähne, W | 1 |
| Pols, HA; Wittenberg, J | 1 |
| Flik, KR; Gardner, MJ; Lane, JM; Mooar, P | 1 |
| Välimäki, MJ | 1 |
| Francis, RM; Tuck, SP | 1 |
| Colao, A; Lombardi, G; Mastrantonio, P; Morelli, M; Nappi, C; Orio, F; Palomba, S; Pellicano, M; Russo, T; Zullo, F | 1 |
| Delling, G; Heilmann, P; Kasperk, C; Mehl, B; Nawroth, P; Schlindwein, I; Voia, C; Ziegler, R | 1 |
| Baranauskaite, A; Savickiene, A | 1 |
| Begerow, B; Hinz, C; Minne, HW; Pfeifer, M; Pollähne, W | 1 |
| Broy, SB; Derosa, AM; Harrington, JT; Licata, AA; Shewmon, DA | 1 |
| Begerow, B; Minne, HW; Pfeifer, M; Pollähne, W | 1 |
| Bartl, R | 2 |
| Matsumoto, T | 1 |
| Begerow, B; Minne, HW; Pfeifer, M | 1 |
| Reincke, M | 1 |
| Chao, HT; Crans, GG; Farooqi, A; Gonzaga, F; Huang, KE; Ismail, NM; Kung, AW; Loh, FH; Need, AG; Rachman, IA; Sriram, U; Taechakraichana, N; Thiebaud, D; Wong, M | 1 |
| Martens, MG | 1 |
| Kafka, A; Kreienberg, R | 1 |
| Ettinger, B; Grove, MR; Hammond, CS; Hebert, GM; Moncur, MM; Pressman, AR; Ray, GT; Tosteson, AN | 1 |
| Lakatos, P | 1 |
| Freudenstein, J; Nisslein, T | 1 |
| Erviti, J | 1 |
| Center, JR; Eisman, JA; Nguyen, TV | 1 |
| Bonn, D | 1 |
| Hosoi, T | 1 |
| Yoh, K | 1 |
| Crans, GG; Delmas, PD; Diez-Perez, A; Pinette, KV; Reginster, JY; Sarkar, S | 1 |
| Jordan, VC | 4 |
| Braddon, J; Phillips, P | 1 |
| Cheung, AM; Diaz-Granados, N; Dodin, S; Feig, DS; Kapral, M | 1 |
| Darlington, LG; Forrest, CM; Kennedy, A; Stone, TW; Stoy, N | 1 |
| McCombs, JS; McLaughlin-Miley, C; Shi, J; Thiebaud, P | 1 |
| Balen, I; Balen-Jandrić, M; Bistrović, D; Cosić, V; Leko, N; Miskić, B; Miskić, D; Samardzić, P | 1 |
| Barrett-Connor, E; Cox, DA; Harper, K; Sarkar, S | 1 |
| Eng-Wong, J; Zujewski, JA | 1 |
| Drieling, RL; Hersh, AL; Stafford, RS | 1 |
| Fallon, MA; Finkelstein, JS; Lee, H; Smith, MR | 1 |
| Clarke, A; Layton, D; Shakir, SA; Wilton, LV | 1 |
| Nakamura, T | 3 |
| Kung, AW | 1 |
| Miki, T; Tomiyoshi, Y | 1 |
| Borgström, F; Johnell, O; Jönsson, B; Kanis, JA; Oden, A; Sykes, D | 1 |
| Hosking, DJ; Pande, I | 2 |
| de la Piedra, C; García-Moreno, C; Méndez-Dávila, C; Turbì, C | 1 |
| Brixen, K; Mosekilde, L; Vestergaard, P | 1 |
| Okazaki, R | 1 |
| Hetzell, CB | 1 |
| Antoniucci, DM; Black, DM; Blackwell, T; Sellmeyer, DE; Vittinghoff, E | 1 |
| Bashir, A; Cheung, J; Fogelman, I; Grigoriadis, AE; Hampson, G; Mak, YT; McGowan, NW; Sankaralingam, S | 1 |
| Cummings, SR; Diez-Perez, A; Eastell, R; Goemaere, S; Harris, ST; Kulkarni, PM; Qu, Y; Siddhanti, SR; Siris, ES; Song, J; Stock, JL; Wong, M; Zanchetta, JR | 1 |
| Iwamoto, J; Rowley, E; Sato, M; Schmidt, A; Stanfield, L; Takeda, T; Yeh, JK | 1 |
| Ellerbeck, EF; Jachna, CM; Rigler, SK; Shireman, TI; Whittle, J | 1 |
| Case, M; Qu, Y | 1 |
| Binkowitz, B; Capizzi, T; Chen, X; Luo, X; Quan, H; Wei, L | 1 |
| Frosch, KH; Rack, T; Sehmisch, S; Seidlová-Wuttke, D; Stürmer, EK; Stürmer, KM; Wille, J; Wuttke, W | 1 |
| Reginster, JY; Sarlet, N | 1 |
| Miki, T; Saito, S | 1 |
| Takada, J | 1 |
| Lane, J | 1 |
| Duerring, SA; Emmett, MK; Lester, MD; Pfister, AK; Saville, PD; Welch, CA | 1 |
| He, JW; Hu, YQ; Huang, QR; Li, M; Liu, YJ; Qin, YJ; Zhang, ZL | 1 |
| de Vernejoul, MC | 1 |
| Brookhart, MA; Choudhry, NK; Fischer, MA; Solomon, DH; Udell, JA | 1 |
| Vastag, B | 1 |
| Boccuzzi, SJ; Downey, TW; Foltz, SH; Kahler, KH; Omar, MA | 1 |
| Wooltorton, E | 1 |
| Fassbender, WJ; Kurth, A; Stumpf, UC | 1 |
| Asano, S; Kanematsu, M; Kikkawa, H; Kinoshita, M; Mitamura, M; Xiang, A | 1 |
| Kleerekoper, M | 2 |
| Gennari, L; Martini, G; Merlotti, D; Nuti, R | 1 |
| Odvina, CV | 1 |
| Kato, S | 1 |
| Kaji, H; Sugimoto, T | 1 |
| Nozaki, M | 1 |
| Qu, Y; Sarkar, S | 1 |
| Adami, S; Agnusdei, D; Gentilella, R; Iori, N; Isaia, G; Luisetto, G; Minisola, S; Nuti, R; Sinigaglia, L | 1 |
| Johnson, KA | 1 |
| Roux, C | 1 |
| Cremers, S; Garnero, P | 1 |
| Jordan, VC; Morrow, M | 2 |
| Adachi, JD; Dolovich, L; Kennedy, CC; Lau, E; Papaioannou, A | 1 |
| Askins, DG; Bushardt, RL; Ragucci, KR; Turner, JL | 1 |
| Cherkas, LF; Richards, JB; Spector, TD | 1 |
| Arnold, M; Avorn, J; Brookhart, MA; Finkelstein, JS; Katz, JN; Mogun, H; Patrick, AR; Polinski, JM; Solmon, DH | 1 |
| Labovitz, JM; Revill, K | 1 |
| Oberender, P; Zerth, J | 1 |
| Miki, T | 1 |
| Cetin, A; Dane, B; Dane, C; Erginbas, M | 1 |
| Young, D | 1 |
| Inoue, D | 1 |
| Christodoulakos, GE; Marín, F; Mellström, D; Nickelsen, T; Pavo, I; Petto, H; Ringe, JD | 1 |
| Buckwalter, JG; Geiger, AM; Handler, J; Howes, J; Lehmer, RR; Parsons, TD | 1 |
| Caeiro, JR; Cano, A; Dapía, S; del Val, R; García-Pérez, MA; Hermenegildo, C; Noguera, I; Pineda, B | 1 |
| González Macías, J; Olmos Martínez, JM | 1 |
| Soen, S | 1 |
| Hagino, H | 1 |
| Tanaka, Y | 1 |
| Iwamoto, J; Matsumoto, H; Sato, Y; Takeda, T; Uzawa, M | 1 |
| Badimon, JJ; Cardoso, L; Choi, BG; Fuster, V; Ibanez, B; Schaffler, MB; Tunstead, J; Vilahur, G; Viles-Gonzalez, JF; Yadegar, D; Zafar, MU | 1 |
| Chao, HT; Cheng, MH; Lee, WL; Wang, PH | 1 |
| Gärtner, R | 1 |
| Brookhart, MA; Cadarette, SM; Katz, JN; Solomon, DH; Stedman, MR; Stürmer, T | 1 |
| Bryant, HU; Kim, J; Sato, M; Short, LL; Slemenda, CW | 1 |
| Hoszowski, K | 1 |
| Lips, P; Netelenbos, JC | 1 |
| Rackoff, P | 1 |
| Smigel, K | 1 |
| Asplin, I; Baer, P; Brown, HR; Henke, B; Jones, SA; McDonnell, DP; Morris, DC; Norris, JD; Sauls, H; Wagner, BL; Willson, TM; Wolfe, S | 1 |
| Balfour, JA; Goa, KL | 1 |
| Oliaro, A | 1 |
| Zaidi, M | 1 |
| Tonino, RP | 1 |
| O'Mahony, D | 1 |
| Ullom-Minnich, P | 1 |
| Meiner, SE | 1 |
| Rubin, CD | 1 |
| Dunlop, MB; Lane, NE | 1 |
| Gardner, N | 1 |
| Evans, A; Healy, D; Vollenhoven, B | 1 |
| Eppes, PG; Wilson, CT; Wozniak, TF | 1 |
| Beardsworth, SA; Purdie, DW | 1 |
| Burckhardt, P | 1 |
| Cockcroft, N; Dahllund, J; Härkönen, P; Hemminki, K; Kangas, L; Koskinen, M; Laine, A; Peng, Z; Qu, Q; Väänänen, K; Zheng, H | 1 |
| Han, RK; Heisey, R; Pimlott, N | 1 |
| Ito, M; Miyaura, C; Nozawa, S; Ohta, H; Onoe, Y; Suda, T | 1 |
| Audran, M | 1 |
| Eisman, JA; Sambrook, PN | 1 |
| Ciaccia, AV; Draper, MW; Licata, AA; Wong, M | 1 |
| Einhorn, TA | 1 |
| Boersma, CJ; Dijkema, R; Mosselman, S; Mulder, WR; Olijve, W; van den Wijngaard, A; van Zoelen, EJ | 1 |
| Dayspring, T | 1 |
| Ettinger, B | 1 |
| Green, SS; Milott, JL; Schapira, MM | 1 |
| Halbekath, J | 1 |
| Baran, DT | 1 |
| Chapurlat, R; Delmas, PD | 1 |
| Anderson, PW; Moscarelli, E | 1 |
| Schein, JR; Sewell, K | 1 |
| Delmas, PD; Eastell, R; Garnero, P; Seibel, MJ; Stepan, J | 1 |
| Mamounas, EP | 1 |
| Moore, HC | 1 |
| Kleerekoper, M; Schein, JR | 1 |
| Lane, NE | 1 |
| Hoon, TS; Leok, GC; Yosipovitch, G | 1 |
| Canfield, G | 1 |
| Cauley, JA; Cummings, SR; Eckert, S; Jamal, S; Krueger, KA; Lippman, ME; Sashegyi, A; Walls, EL | 1 |
| Chan, HW | 1 |
| Patlak, M | 1 |
| Mincey, BA | 1 |
| McClung, B; McClung, M | 1 |
| Bauer, DC; Chapurlat, RD; Cummings, SR; Ewing, SK | 1 |
| Gapstur, S; Jordan, VC; Morrow, M | 1 |
| Anderson, PW; Barrett-Connor, E; Cox, DA; Harper, K; Mosca, L; O'Gorman, J; Sarkar, S | 1 |
| Anderson, PW; Cox, DA; Dean, RA; Sashegyi, A; Tracy, RP; Walsh, BW | 1 |
| Kemner, JE; O'Connor, LJ; Ohsfeldt, RL; Solomon, TE | 1 |
| Bruder, JM; Rubin, CD; Wang, CY | 1 |
| Atkinson, EJ; Doran, PM; Khosla, S; Riggs, BL | 1 |
| Kellen, JA | 1 |
| Cortet, B | 1 |
| Sherman, S | 1 |
| Jordan, VC; Park, WC | 1 |
| Clarkson, TB | 1 |
| Bilezikian, JP; Ettinger, B | 1 |
| Bentrem, DJ; Craig Jordan, V | 1 |
| Ishii, J | 1 |
| Anthony, M; Arun, B; Dunn, B | 1 |
| Alba, E; Colla, F; Farina, C; Mazzoleni, A; Ragonesi, G | 1 |
136 review(s) available for raloxifene hydrochloride and Osteoporosis
| Article | Year |
|---|---|
The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Ibandronic Acid; Network Meta-Analysis; Osteoporosis; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome | 2023 |
Minodronate in the treatment of osteoporosis: A systematic review and meta-analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Bone Density Conservation Agents; Case-Control Studies; Collagen Type I; Creatinine; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Tartrate-Resistant Acid Phosphatase; Treatment Outcome; Vitamin D | 2020 |
Osteoporosis - risk factors, pharmaceutical and non-pharmaceutical treatment.
Topics: Cholecalciferol; Denosumab; Dietary Supplements; Diphosphonates; Exercise; Humans; Kinesiology, Applied; Osteoporosis; Raloxifene Hydrochloride; Risk Factors; Teriparatide; Thiophenes | 2021 |
Benefits and Harms of Osteoporosis Medications in Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis.
Topics: Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Osteoporosis; Raloxifene Hydrochloride; Renal Insufficiency, Chronic; Teriparatide | 2017 |
2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.
Topics: Bone Density Conservation Agents; Calcium, Dietary; Consensus; Denosumab; Diphosphonates; Glucocorticoids; Humans; Osteoporosis; Osteoporotic Fractures; Raloxifene Hydrochloride; Rheumatic Diseases; Rheumatology; Societies, Medical; Teriparatide; United States; Vitamin D | 2017 |
Fracture risk and treatment in chronic kidney disease.
Topics: Absorptiometry, Photon; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Fractures, Bone; Humans; Osteoporosis; Raloxifene Hydrochloride; Renal Insufficiency, Chronic; Risk Factors | 2018 |
The benefits of estrogen or selective estrogen receptor modulator on kidney and its related disease-chronic kidney disease-mineral and bone disorder: osteoporosis.
Topics: Bone Density; Estrogens; Female; Humans; Kidney; Osteoporosis; Raloxifene Hydrochloride; Renal Dialysis; Renal Insufficiency, Chronic; Selective Estrogen Receptor Modulators | 2013 |
Update on raloxifene: mechanism of action, clinical efficacy, adverse effects, and contraindications.
Topics: Blood Coagulation; Bone and Bones; Breast; Breast Neoplasms; Contraindications; Endometrium; Female; Humans; Hypercholesterolemia; Osteoporosis; Raloxifene Hydrochloride; Receptors, Estrogen; Risk Factors; Selective Estrogen Receptor Modulators; Thromboembolism | 2013 |
Use of SERMs for treatment in postmenopausal women.
Topics: Breast Neoplasms; Clinical Trials as Topic; Dyspareunia; Estrogens, Conjugated (USP); Female; Hot Flashes; Humans; Indoles; Osteoporosis; Osteoporosis, Postmenopausal; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Toremifene | 2014 |
[Anti-osteoporosis drugs based on the guidelines for the Prevention and Treatment of Osteoporosis (2011 edition) ].
Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Cholecalciferol; Denosumab; Diphosphonates; Drug Therapy, Combination; Fractures, Spontaneous; Humans; Ibandronic Acid; Molecular Targeted Therapy; Osteoporosis; Practice Guidelines as Topic; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures; Teriparatide | 2014 |
The role of teriparatide in sequential and combination therapy of osteoporosis.
Topics: Bone Density Conservation Agents; Diphosphonates; Drug Therapy, Combination; Female; Humans; Male; Osteoporosis; Raloxifene Hydrochloride; Teriparatide; Treatment Failure | 2014 |
Efficacy and safety of currently marketed anti-osteoporosis medications.
Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Diphosphonates; Humans; Indoles; Osteoporosis; Parathyroid Hormone; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Thiophenes | 2014 |
Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
Topics: Animals; Breast; Breast Neoplasms; Drug Therapy, Combination; Estradiol; Estrogen Antagonists; Estrogens; Estrogens, Conjugated (USP); Female; Fulvestrant; Humans; Indoles; Osteoporosis; Postmenopause; Protective Factors; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene | 2015 |
Perioperative Medical Management of Spine Surgery Patients With Osteoporosis.
Topics: Aged; Aged, 80 and over; Anabolic Agents; Bone Density Conservation Agents; Calcitonin; Calcium; Diphosphonates; Estrogens; Female; Humans; Male; Osteoporosis; Parathyroid Hormone; Perioperative Care; Raloxifene Hydrochloride; Recombinant Proteins; Selective Estrogen Receptor Modulators; Spinal Diseases; Spinal Fusion; Vitamin D | 2015 |
Emerging therapeutic concepts for muscle and bone preservation/building.
Topics: Anabolic Agents; Animals; Bone Density; Bone Remodeling; Bone Resorption; Denosumab; Diphosphonates; Fractures, Bone; Humans; Muscle, Skeletal; Osteoporosis; Raloxifene Hydrochloride | 2015 |
Neurocognitive, Neuroprotective, and Cardiometabolic Effects of Raloxifene: Potential for Improving Therapeutic Outcomes in Schizophrenia.
Topics: Animals; Antipsychotic Agents; Humans; Osteoporosis; Raloxifene Hydrochloride; Schizophrenia; Selective Estrogen Receptor Modulators; Treatment Outcome | 2016 |
[Muscle and bone health as a risk factor of fall among the elderly. Role of raloxifene in the prevention of osteoporotic fractures].
Topics: Bone Density Conservation Agents; Humans; Osteoporosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Spinal Fractures; Spine | 2008 |
[Role of estrogen and selective estrogen receptor modulators in anti-aging].
Topics: Aging; Animals; Bone and Bones; Bone Density; Breast Neoplasms; Estrogen Replacement Therapy; Estrogens; Female; Fractures, Bone; Humans; Osteoporosis; Perimenopause; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators | 2008 |
[Daily practice using the guidelines for prevention and treatment of osteoporosis. Utilization of metabolic markers of bone in daily osteoporosis practice].
Topics: Biomarkers; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Spontaneous; Humans; Osteoporosis; Raloxifene Hydrochloride; Risk Assessment; Vitamin K 2 | 2008 |
Clinical challenges in the management of osteoporosis.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Therapy, Combination; Female; Humans; Osteoporosis; Raloxifene Hydrochloride; Vitamin D; Vitamin D Deficiency | 2008 |
Treatment of osteoporosis: all the questions we still cannot answer.
Topics: Age Factors; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Therapy, Combination; Fractures, Bone; Hormone Replacement Therapy; Humans; Organometallic Compounds; Osteoporosis; Raloxifene Hydrochloride; Teriparatide; Thiophenes; Time Factors | 2008 |
[Treatment of osteoporosis in octogenarians].
Topics: Aged, 80 and over; Attitude to Health; Bone Density Conservation Agents; Bone Resorption; Calcitonin; Diphosphonates; Fractures, Bone; Frail Elderly; Humans; Osteoporosis; Perception; Raloxifene Hydrochloride | 2008 |
Parathyroid hormone treatment for osteoporosis.
Topics: Anabolic Agents; Bone Density Conservation Agents; Diphosphonates; Drug Therapy, Combination; Female; Hormone Replacement Therapy; Humans; Male; Osteoporosis; Parathyroid Hormone; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Treatment Outcome | 2008 |
The NSABP Study of Tamoxifen and Raloxifene (STAR) trial.
Topics: Breast Neoplasms; Female; Humans; Middle Aged; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2009 |
[Drug selection guide for osteoporosis determined by the clinical staging, pathophysiology and age].
Topics: Age Factors; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Calcium; Diphosphonates; Drug Therapy, Combination; Female; Hip Fractures; Humans; Osteoporosis; Raloxifene Hydrochloride; Risk; Vitamin D | 2009 |
[Bone quality].
Topics: Absorptiometry, Photon; Alendronate; Bone and Bones; Bone Density Conservation Agents; Clinical Trials as Topic; Diagnostic Imaging; Diphosphonates; Hip Fractures; Humans; Osteoporosis; Raloxifene Hydrochloride; Risk Assessment | 2009 |
[Bone metabolic marker for osteoporosis].
Topics: Acid Phosphatase; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Resorption; Collagen Type I; Diphosphonates; Female; Fractures, Bone; Humans; Isoenzymes; Osteoporosis; Peptides; Raloxifene Hydrochloride; Risk Assessment; Tartrate-Resistant Acid Phosphatase | 2009 |
[Evidence for the selective estrogen receptor modulator raloxifene--its pharmacological characteristics, efficacy and safety profiles].
Topics: Bone and Bones; Bone Density; Clinical Trials as Topic; Evidence-Based Medicine; Fractures, Bone; Fractures, Spontaneous; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2009 |
[Combination therapy for osteoporosis].
Topics: Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Drug Therapy, Combination; Humans; Osteoporosis; Parathyroid Hormone; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Vitamin D | 2009 |
Pharmacotherapeutic management of osteoprosis and osteopenia.
Topics: Algorithms; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcitonin; Diphosphonates; Drug Monitoring; Estrogen Replacement Therapy; Fractures, Bone; Humans; Mass Screening; Nurse Practitioners; Nursing Assessment; Osteoporosis; Patient Selection; Practice Guidelines as Topic; Primary Health Care; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Teriparatide | 2009 |
[Therapeutic considerations on secondary osteoporosis caused by diabetes mellitus].
Topics: Bone Density Conservation Agents; Diabetes Complications; Diphosphonates; Fractures, Bone; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Vitamin D; Vitamin K | 2009 |
Approaches to osteoporosis: screening and implementing treatment in clinical practice.
Topics: Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Humans; Mass Screening; Medication Adherence; Osteoporosis; Practice Guidelines as Topic; Primary Health Care; Raloxifene Hydrochloride; Risk Assessment | 2009 |
Current and emerging therapies for osteoporosis.
Topics: Bone and Bones; Bone Density Conservation Agents; Bone Resorption; Calcitonin; Diphosphonates; Drug Therapy, Combination; Estrogens; Humans; Osteoporosis; Raloxifene Hydrochloride; Teriparatide; Treatment Outcome | 2009 |
[Effects of SERMs on bone health. Effects of raloxifene and bisphosphonate on bone quality in osteoporosis: collagen cross-links, mineralization, and bone strength].
Topics: Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcification, Physiologic; Collagen; Diphosphonates; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Stimulation, Chemical | 2010 |
[Effects of SERMs on bone health. SERM and metabolic markers of bone].
Topics: Acid Phosphatase; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Humans; Isoenzymes; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tartrate-Resistant Acid Phosphatase | 2010 |
[Effects of SERMs on bone health. The potential of SERM in the care of chronic kidney disease-mineral bone and disorders].
Topics: Bone Density Conservation Agents; Bone Diseases, Metabolic; Chronic Disease; Evidence-Based Medicine; Fractures, Spontaneous; Humans; Kidney Diseases; Osteoporosis; Parathyroid Hormone; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Vitamin D | 2010 |
Cinacalcet for the treatment of primary hyperparathyroidism.
Topics: Bone Density; Bone Density Conservation Agents; Calcimimetic Agents; Calcitonin; Cinacalcet; Diphosphonates; Estrogen Replacement Therapy; Estrogens; Female; Humans; Hyperparathyroidism, Primary; Naphthalenes; Osteoporosis; Raloxifene Hydrochloride | 2011 |
Management of osteoporosis in CKD Stages 3 to 5.
Topics: Absorptiometry, Photon; Accidental Falls; Aged; Animals; Bone Density; Bone Density Conservation Agents; Calcitonin; Comorbidity; Diphosphonates; Female; Glomerular Filtration Rate; Humans; Life Style; Magnetic Resonance Imaging; Muscle Strength; Nandrolone; Nandrolone Decanoate; Nitric Oxide; Osteoporosis; Parathyroid Hormone; Phosphates; Raloxifene Hydrochloride; Renal Insufficiency, Chronic; Selective Estrogen Receptor Modulators; Teriparatide; Tomography, X-Ray Computed; Vitamin D Deficiency | 2010 |
[Secondary osteoporosis UPDATE. Drugs under development for metabolic bone disease].
Topics: Anabolic Agents; Bone Density Conservation Agents; Bone Diseases, Metabolic; Cathepsins; Diphosphonates; Drug Discovery; Humans; Osteoporosis; Raloxifene Hydrochloride; RANK Ligand; Selective Estrogen Receptor Modulators; Teriparatide | 2010 |
[Secondary osteoporosis UPDATE. Treatment of male osteoporosis. Testosterone replacement therapy etc].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Diphosphonates; Fractures, Spontaneous; Hormone Replacement Therapy; Humans; Life Style; Male; Osteoporosis; Raloxifene Hydrochloride; RANK Ligand; Selective Estrogen Receptor Modulators; Teriparatide; Testosterone | 2010 |
A comparison between bisphosphonates and other treatments for osteoporosis.
Topics: Bone Density Conservation Agents; Diphosphonates; Drug Costs; Drug Monitoring; Female; France; Humans; Male; Medication Adherence; Organometallic Compounds; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Teriparatide; Thiophenes | 2010 |
Modulators of androgen and estrogen receptor activity.
Topics: Androgen Receptor Antagonists; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Male; Osteoporosis; Prostatic Neoplasms; Raloxifene Hydrochloride; Receptors, Androgen; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen | 2010 |
[Pharmacotherapy of osteoporosis accompanied by lifestyle-related diseases].
Topics: Adrenergic beta-Antagonists; Animals; Cardiovascular Diseases; Diabetes Complications; Diphosphonates; Dyslipidemias; Fractures, Bone; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypoglycemic Agents; Life Style; Osteogenesis; Osteoporosis; Raloxifene Hydrochloride; Thiazolidinediones; Vitamin D | 2011 |
[Diagnostic imaging of treatment in osteoporosis: SERM].
Topics: Absorptiometry, Photon; Bone and Bones; Bone Density; Female; Hip Fractures; Humans; Indoles; Osteoporosis; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Tomography, X-Ray Computed | 2011 |
[Bone and calcium metabolism in patients with rheumatoid arthritis].
Topics: Animals; Arthritis, Rheumatoid; Bone and Bones; Calcium; Disease Models, Animal; Disease Progression; Estrogen Replacement Therapy; Estrogens; Female; Humans; Inflammation Mediators; Joints; Male; Menopause; Osteoporosis; Pregnancy; Pregnancy Complications; Raloxifene Hydrochloride | 2011 |
The mechanism of vascular calcification - a systematic review.
Topics: Atherosclerosis; Calciphylaxis; Cardiovascular Diseases; Gonadal Steroid Hormones; Heart Valves; Humans; Metabolic Diseases; Models, Biological; Osteoporosis; Raloxifene Hydrochloride; Vascular Calcification | 2012 |
[Combination or sequential treatment using PTH and anti-resorption therapies].
Topics: Animals; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Osteoporosis; Osteoporotic Fractures; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Teriparatide; Time Factors; Zoledronic Acid | 2012 |
Osteoporosis in chronic liver disease.
Topics: Absorptiometry, Photon; Adrenal Cortex Hormones; Bilirubin; Bone Density; Calcitonin; Calcium, Dietary; Diphosphonates; Humans; Insulin-Like Growth Factor I; Liver Diseases; Malnutrition; Motor Activity; Osteoporosis; Raloxifene Hydrochloride; RANK Ligand; Risk Factors; Tumor Necrosis Factor-alpha; Vitamin D; Vitamin K Deficiency | 2013 |
Osteoporosis.
Topics: Accidental Falls; Adult; Aged; Bone Density; Calcitonin; Calcium, Dietary; Decision Making; Diphosphonates; Female; Hormone Replacement Therapy; Humans; Life Style; Male; Middle Aged; Osteoporosis; Parathyroid Hormone; Raloxifene Hydrochloride; Vitamin D | 2002 |
[Osteoporosis: prevention of bone loss and fractures].
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Diseases, Metabolic; Diagnosis, Differential; Exercise; Female; Fractures, Bone; Hip Fractures; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Spinal Fractures; Time Factors; Tomography, X-Ray Computed | 2002 |
[Osteoporosis].
Topics: Alendronate; Bone Density; Drug Therapy, Combination; Estrogen Replacement Therapy; Etidronic Acid; Evidence-Based Medicine; Female; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid | 2002 |
[Osteoporosis].
Topics: Animals; Bone Resorption; Calcitriol; Clinical Trials as Topic; Diphosphonates; Humans; Osteoblasts; Osteoclasts; Osteogenesis; Osteoporosis; Parathyroid Hormone; Raloxifene Hydrochloride; Vitamin D | 2002 |
[Rehabilitation in osteoporosis].
Topics: Alendronate; Ergonomics; Exercise Therapy; Female; Fractures, Bone; Humans; Male; Osteoporosis; Pain; Physical Therapy Modalities; Psychotherapy; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spine | 2003 |
Risk of fracture and treatment to prevent osteoporosis-related fracture in postmenopausal women. A review.
Topics: Aged; Alendronate; Calcitonin; Clinical Trials as Topic; Diphosphonates; Estrogen Antagonists; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Risk Factors | 2003 |
Selective estrogen-receptor modulators.
Topics: Female; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2003 |
[Treatment of osteoporosis].
Topics: Bone Density; Calcitonin; Calcium Compounds; Diphosphonates; Estrogen Replacement Therapy; Female; Humans; Male; Norpregnenes; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Vitamin D | 2003 |
Osteoporosis: underrated, underdiagnosed and undertreated.
Topics: Aged; Bone Density; Calcium, Dietary; Cholecalciferol; Diagnostic Errors; Diphosphonates; Estrogen Replacement Therapy; Female; Fractures, Spontaneous; Humans; Male; Osteoporosis; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Treatment Failure | 2004 |
[Prevention of fractures with therapeutic agents for osteoporosis].
Topics: Aged; Bone Density; Diphosphonates; Estrogen Receptor Modulators; Estrogen Replacement Therapy; Femoral Neck Fractures; Humans; Meta-Analysis as Topic; Osteoporosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Spinal Fractures | 2004 |
[Quality of life before and after medical treatments in osteoporosis patients].
Topics: Calcitonin; Diphosphonates; Estrogen Replacement Therapy; Fractures, Bone; Humans; Osteoporosis; Quality of Life; Raloxifene Hydrochloride; Sickness Impact Profile; Surveys and Questionnaires; Vitamin D | 2004 |
Selective estrogen receptor modulation: concept and consequences in cancer.
Topics: Apoptosis; Breast Neoplasms; Dimerization; Drug Resistance; Endometrial Neoplasms; Estrogen Antagonists; Estrogen Receptor Modulators; Estrogen Replacement Therapy; Estrogens; Female; Hot Flashes; Humans; Osteoporosis; Protein Binding; Protein Conformation; Protein Interaction Mapping; Raloxifene Hydrochloride; Receptors, Estrogen; Signal Transduction; Tamoxifen | 2004 |
Raloxifene and its role in breast cancer prevention.
Topics: Breast Neoplasms; Chemoprevention; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Osteoporosis; Raloxifene Hydrochloride; Risk Factors; Signal Transduction | 2004 |
[Selective estrogen receptor modulator].
Topics: Female; Fractures, Spontaneous; Humans; Osteoporosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators | 2004 |
[Bone quality in treatment with raroxifene ].
Topics: Bone Density; Etidronic Acid; Evidence-Based Medicine; Femoral Neck Fractures; Humans; Meta-Analysis as Topic; Osteoporosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Regression Analysis; Reproducibility of Results; Risedronic Acid; Spinal Fractures; Testosterone | 2004 |
Management of osteoporosis in Hong Kong.
Topics: Bone Density; Calcium, Dietary; Cost-Benefit Analysis; Estrogen Replacement Therapy; Health Education; Hong Kong; Humans; Life Style; Osteoporosis; Parathyroid Hormone; Primary Prevention; Quality of Life; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Vitamin D | 2004 |
[Evaluation of osteoporosis treatment efficacy by bone mass measurement].
Topics: Absorptiometry, Photon; Bone Density; Diphosphonates; Drug Monitoring; Fractures, Bone; Humans; Osteoporosis; Raloxifene Hydrochloride; Risk; Treatment Outcome | 2004 |
Oral antiresorptive therapy.
Topics: Administration, Oral; Alendronate; Anabolic Agents; Bone Resorption; Diphosphonates; Drug Therapy, Combination; Etidronic Acid; Fractures, Bone; Glucocorticoids; Humans; Ibandronic Acid; Osteoporosis; Raloxifene Hydrochloride; Risedronic Acid; Selective Estrogen Receptor Modulators; Teriparatide | 2005 |
[Treatment of osteoporosis with antiresorptive drugs].
Topics: Bone Density; Bone Resorption; Calcitonin; Calcium; Cholecalciferol; Diphosphonates; Estradiol; Estrogens, Conjugated (USP); Female; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Progesterone; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Vitamin D | 2005 |
[SERMs: an update for clinicians].
Topics: Animals; Bone and Bones; Bone Resorption; Drug Design; Evidence-Based Medicine; Fractures, Spontaneous; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2005 |
[Raloxifene and bone quality issues].
Topics: Bone Density; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2005 |
Oral antiresorptive therapy.
Topics: Administration, Oral; Aged; Alendronate; Diphosphonates; Drug Therapy, Combination; Etidronic Acid; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2004 |
The treatment of severe postmenopausal osteoporosis : a review of current and emerging therapeutic options.
Topics: Alendronate; Bone Density; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Teriparatide | 2006 |
[Application of anti-resorptive drugs for the treatment of osteoporosis].
Topics: Aged; Alendronate; Bone Resorption; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis; Raloxifene Hydrochloride; Risedronic Acid | 2006 |
[Effect of raloxifene as a SERM on bone metabolism].
Topics: Bone and Bones; Bone Density; Bone Resorption; Female; Fractures, Bone; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2006 |
Osteoporosis prevention and therapy: preserving and building strength through bone quality.
Topics: Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcitonin; Diphosphonates; Estrogen Replacement Therapy; Female; Humans; Male; Organometallic Compounds; Osteoporosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Thiophenes | 2006 |
Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis.
Topics: Animals; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Structure-Activity Relationship | 2006 |
Osteoporosis: how should it be treated?
Topics: Bone Density; Bone Resorption; Calcitonin; Diphosphonates; Drug Therapy, Combination; Estrogens; Humans; Osteoporosis; Parathyroid Hormone; Peptide Fragments; Raloxifene Hydrochloride | 2006 |
[Molecular mechanism of tissue-specific actions of SERM].
Topics: Bone Density Conservation Agents; Female; Humans; Organ Specificity; Osteoporosis; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Transcription, Genetic | 2006 |
[Anabolic treatment for osteoporosis: PTH treatment].
Topics: Anabolic Agents; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Synergism; Drug Therapy, Combination; Fractures, Bone; Humans; Organometallic Compounds; Osteoporosis; Parathyroid Hormone; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Thiophenes | 2006 |
[SERM].
Topics: Female; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2006 |
Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers; Bone Density; Bone Diseases, Metabolic; Bone Neoplasms; Bone Remodeling; Bone Resorption; Calcitonin; Cathepsin K; Cathepsins; Collagen Type I; Denosumab; Diphosphonates; Drug Administration Schedule; Drug Design; Female; Humans; Organometallic Compounds; Osteitis Deformans; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; RANK Ligand; Thiophenes | 2006 |
The current status of breast cancer chemoprevention: a star is born.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Clinical Trials as Topic; Endometrial Neoplasms; Female; Humans; Osteoporosis; Raloxifene Hydrochloride; Risk; Risk Assessment; Tamoxifen | 2007 |
Patient adherence to osteoporosis medications: problems, consequences and management strategies.
Topics: Aged; Bone Density Conservation Agents; Calcium; Diphosphonates; Drug Therapy, Combination; Female; Hormone Replacement Therapy; Humans; Male; Micronutrients; Osteoporosis; Patient Compliance; Raloxifene Hydrochloride; Vitamin D | 2007 |
Non-estrogen treatments for osteoporosis: an evidence-based review.
Topics: Bone Density Conservation Agents; Calcitonin; Diphosphonates; Evidence-Based Medicine; Female; Humans; Osteoporosis; Raloxifene Hydrochloride; Teriparatide | 2006 |
Osteoporosis: pathogenesis, new therapies and surgical implications.
Topics: Arthritis; Autoimmune Diseases; Bone Density; Bone Density Conservation Agents; Calcitonin; Diphosphonates; Humans; Osteoporosis; Raloxifene Hydrochloride; Surgical Procedures, Operative | 2007 |
[Recent topics in the treatment of osteoporosis in Japan].
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Humans; Osteoporosis; Raloxifene Hydrochloride | 2007 |
[Current and future prospects for anti-osteoporotic drugs].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Cholecalciferol; Clinical Trials as Topic; Denosumab; Diphosphonates; Drug Administration Schedule; Drug Design; Humans; Organometallic Compounds; Osteoporosis; Parathyroid Hormone; Patient Compliance; Raloxifene Hydrochloride; RANK Ligand; Selective Estrogen Receptor Modulators; Thiophenes | 2007 |
[Osteoporosis in cancer survivors].
Topics: Age Factors; Aged; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Fractures, Bone; Humans; Hypogonadism; Male; Middle Aged; Neoplasms; Osteoporosis; Prostatic Neoplasms; Radiotherapy; Raloxifene Hydrochloride; Retrospective Studies; Risk Factors | 2007 |
Tamoxifen: catalyst for the change to targeted therapy.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Female; History, 20th Century; History, 21st Century; Humans; Osteoporosis; Raloxifene Hydrochloride; Rats; Selective Estrogen Receptor Modulators; Tamoxifen | 2008 |
[Adverse events of drugs for the treatment of osteoporosis].
Topics: Bone Density Conservation Agents; Cardiovascular Diseases; Cholecalciferol; Diphosphonates; Gastrointestinal Diseases; Hot Flashes; Humans; Hypercalcemia; Jaw Diseases; Macular Edema; Necrosis; Osteoporosis; Raloxifene Hydrochloride; Venous Thrombosis | 2007 |
[First choice drug for treatment of osteoporosis and the strategic points for choice of drugs].
Topics: Bone Density; Bone Density Conservation Agents; Calcium; Cholecalciferol; Diphosphonates; Evidence-Based Medicine; Femoral Neck Fractures; Humans; Meta-Analysis as Topic; Osteoporosis; Practice Guidelines as Topic; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Spinal Fractures | 2007 |
[Combination therapy for osteoporosis].
Topics: Alendronate; Bone Density Conservation Agents; Calcitonin; Calcium; Cholecalciferol; Diphosphonates; Drug Therapy, Combination; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Vitamin K 2 | 2007 |
[Transplantation and osteoporosis].
Topics: Bone Density Conservation Agents; Diphosphonates; Glucocorticoids; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Organ Transplantation; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2007 |
[Assessment of bone quality. Effects of bisphosphonates, raloxifene, alfacalcidol, and menatetrenone on bone quality: collagen cross-links, mineralization, and microdamage].
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Remodeling; Calcification, Physiologic; Collagen; Diphosphonates; Glycation End Products, Advanced; Humans; Hydroxycholecalciferols; Osteoporosis; Raloxifene Hydrochloride; Vitamin K 2 | 2008 |
The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene.
Topics: Breast Neoplasms; Clinical Trials as Topic; Contraindications; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2008 |
[Osteoporosis in the elderly--diagnosis and treatment].
Topics: Accidental Falls; Age Factors; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Calcium; Diphosphonates; Etidronic Acid; Exercise; Female; Hip Fractures; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Sex Factors; Spinal Fractures; Vitamin D | 2005 |
[Agonists-antagonists of estrogens, their potential use in prophylaxis and treatment of osteoporosis].
Topics: Animals; Bone Density; Estrogen Antagonists; Female; Humans; Osteoporosis; Piperidines; Raloxifene Hydrochloride; Tamoxifen | 1995 |
[Estrogen agonists, especially raloxifene, in the treatment of osteoporosis].
Topics: Adult; Blood Coagulation; Breast; Cardiovascular System; Endometrium; Estrogen Antagonists; Female; Humans; Osteoporosis; Piperidines; Prospective Studies; Raloxifene Hydrochloride | 1996 |
Raloxifene.
Topics: Animals; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Humans; Osteoporosis; Piperidines; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic | 1998 |
Ultrasound and alendronate: new tools for osteoporosis screening and treatment.
Topics: Absorptiometry, Photon; Aged; Alendronate; Calcium; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Male; Mass Screening; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Piperidines; Prognosis; Raloxifene Hydrochloride; Treatment Outcome; Ultrasonography; Vitamin D | 1998 |
Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 6: Executive summary and consensus statement. Proceedings of a conference held at Boar's Head Inn, Charlottesville, Virginia, September 21-23, 1997.
Topics: Breast Neoplasms; Cardiovascular Diseases; Clinical Trials as Topic; Estrogen Antagonists; Estrogens; Estrogens, Non-Steroidal; Female; Humans; Isoflavones; Menopause; Osteoporosis; Phytoestrogens; Piperidines; Plant Preparations; Raloxifene Hydrochloride; Receptors, Estrogen; Survivors | 1999 |
Prevention of osteoporosis and fractures.
Topics: Alendronate; Bone Density; Calcium; Estrogen Replacement Therapy; Estrogens; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Risk; Risk Factors; Vitamin D | 1999 |
An expanding landscape. Osteoporosis. Treatment options today.
Topics: Aged; Calcium; Diphosphonates; Estrogen Antagonists; Female; Humans; Nurse Practitioners; Osteoporosis; Raloxifene Hydrochloride | 1999 |
Treatment considerations in the management of age-related osteoporosis.
Topics: Age Factors; Aged; Bone Density; Calcitonin; Calcium; Diphosphonates; Estrogen Replacement Therapy; Estrogens; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Risk; Risk Factors; Severity of Illness Index | 1999 |
Osteoporosis: diagnosis, prevention, and treatment of established disease.
Topics: Age Factors; Aged; Alendronate; Calcitonin; Calcium Channel Blockers; Calcium, Dietary; Dietary Supplements; Drug Therapy, Combination; Estrogens; Etidronic Acid; Exercise; Female; Hormone Replacement Therapy; Humans; Male; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Risedronic Acid; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Vitamin D | 1999 |
Modern antioestrogens and the coming revolution in women's health care.
Topics: Bone and Bones; Breast Neoplasms; Clomiphene; Estradiol; Estrogen Receptor Modulators; Estrogens, Non-Steroidal; Female; Fulvestrant; Genital Diseases, Female; Humans; Isoflavones; Osteoporosis; Phytoestrogens; Plant Preparations; Plants; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Women's Health | 1999 |
The selective oestrogen receptor modulation: evolution and clinical applications.
Topics: Estrogen Replacement Therapy; Estrogens; Female; Humans; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators | 1999 |
[Selective estrogen receptor modulators (SERM): new substances for hormone replacement therapy].
Topics: Breast Neoplasms; Estrogen Replacement Therapy; Estrogens; Female; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 1999 |
Osteoporosis prevention and treatment.
Topics: Alendronate; Anabolic Agents; Bone Density; Calcitriol; Calcium; Estrogen Replacement Therapy; Etidronic Acid; Evidence-Based Medicine; Female; Humans; Male; Osteoporosis; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risk Factors; Treatment Outcome; Vitamin D | 2000 |
Raloxifene: a new choice for treating and preventing osteoporosis.
Topics: Aged; Calcitonin; Diphosphonates; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators | 2000 |
Raloxifene. Not better than estrogen.
Topics: Aged; Estrogen Replacement Therapy; Female; Fractures, Spontaneous; Humans; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures | 2000 |
Osteoporosis: evaluation and treatment.
Topics: Aged; Alendronate; Calcitonin; Estrogen Replacement Therapy; Female; Humans; Life Style; Male; Osteoporosis; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators | 2000 |
[Drug treatment for the treatment of primary osteoporosis].
Topics: Alendronate; Fluorides; Fractures, Bone; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Vitamin D | 2000 |
Osteoporosis: which current treatments reduce fracture risk?
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Calcium Channel Blockers; Estrogen Replacement Therapy; Etidronic Acid; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Selective Estrogen Receptor Modulators | 2000 |
[Therapeutic strategies for osteoporosis].
Topics: Accidental Falls; Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Hormone Replacement Therapy; Humans; Middle Aged; Nutritional Physiological Phenomena; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Vitamin D | 2000 |
Progress in the prevention of breast cancer: concept to reality.
Topics: Bone Density; Breast Neoplasms; Coronary Disease; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Humans; Osteoporosis; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen | 2000 |
Osteoporosis therapies for rheumatoid arthritis patients: minimizing gastrointestinal side effects.
Topics: Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Estrogen Replacement Therapy; Female; Gastrointestinal Diseases; Humans; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Risk Factors | 2001 |
The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation.
Topics: Biomarkers; Bone Density; Bone Regeneration; Bone Remodeling; Bone Resorption; Diphosphonates; Estrogens; Female; Fractures, Spontaneous; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Periodicity; Prognosis; Raloxifene Hydrochloride; Risk Assessment; Terminology as Topic | 2000 |
Breast cancer chemoprevention.
Topics: Adult; Aged; Aged, 80 and over; Animals; Anticarcinogenic Agents; Breast Neoplasms; Carcinoma; Clinical Trials as Topic; Double-Blind Method; Endometrial Neoplasms; Estrogen Antagonists; Europe; Female; Humans; Hyperlipidemias; Hysterectomy; Mammary Neoplasms, Experimental; Menopause; Mice; Mice, Nude; Middle Aged; Neoplasms, Second Primary; Neoplastic Syndromes, Hereditary; Osteoporosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Risk Factors; Tamoxifen; United States | 2000 |
Comparative safety of bone remodeling agents with a focus on osteoporosis therapies.
Topics: Bone Remodeling; Calcitonin; Calcitriol; Calcium; Diphosphonates; Drug Therapy, Combination; Female; Fluorides; Hormone Replacement Therapy; Humans; Osteoporosis; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators | 2001 |
An update on glucocorticoid-induced osteoporosis.
Topics: Animals; Bone Density; Bone Remodeling; Diphosphonates; Drug Therapy, Combination; Estrogens; Fractures, Bone; Glucocorticoids; Humans; Osteoporosis; Parathyroid Hormone; Raloxifene Hydrochloride; Sodium Fluoride; United Kingdom | 2001 |
Suggested rationale for prevention and treatment of glucocorticoid-induced bone loss in dermatologic patients.
Topics: Adult; Age Factors; Aged; Calcitonin; Calcium; Controlled Clinical Trials as Topic; Densitometry; Diphosphonates; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Exercise; Female; Fractures, Bone; Glucocorticoids; Humans; Male; Meta-Analysis as Topic; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Skin Diseases; Time Factors; Vitamin D | 2001 |
Osteoporosis.
Topics: Absorptiometry, Photon; Aged; Alendronate; Calcitonin; Calcium; Estrogen Replacement Therapy; Female; Humans; Male; Osteoporosis; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators | 2001 |
NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, March 7-29, 2000: highlights of the conference.
Topics: Bone Density; Calcium; Consensus Development Conferences, NIH as Topic; Female; Fractures, Bone; Humans; Male; Osteoporosis; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; United States; Vitamin D | 2001 |
Pharmacologic therapy for the treatment and prevention of osteoporosis.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Diphosphonates; Estrogen Replacement Therapy; Etidronic Acid; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis; Patient Compliance; Patient Selection; Primary Prevention; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Selective Estrogen Receptor Modulators; Treatment Outcome | 2001 |
Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.
Topics: Adult; Aged; Bone and Bones; Breast; Breast Neoplasms; Cardiovascular System; Cinnamates; Clinical Trials as Topic; Coronary Disease; Endometrial Neoplasms; Estrogen Replacement Therapy; Female; Heart; Hot Flashes; Humans; Middle Aged; Models, Biological; Organ Specificity; Osteoporosis; Postmenopause; Premenopause; Prospective Studies; Protein Structure, Tertiary; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Risk; Risk Assessment; Selective Estrogen Receptor Modulators; Stilbenes; Tamoxifen; Thrombophilia; Transcription, Genetic | 2001 |
Evaluation and treatment of postmenopausal osteoporosis.
Topics: Aged; Algorithms; Bone Density; Calcitonin; Calcium; Diphosphonates; Estrogens; Female; Fractures, Bone; Humans; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; United States; Women's Health | 2001 |
Raloxifene.
Topics: Breast Neoplasms; Clinical Trials as Topic; Drugs, Investigational; Endometrium; Female; Humans; Lipoproteins; Osteoporosis; Ovulation; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators | 2001 |
Preventing and treating osteoporosis: strategies at the millennium.
Topics: Diphosphonates; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2001 |
Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention.
Topics: Animals; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Osteoporosis; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen | 2002 |
Raloxifene revisited.
Topics: Aged; Animals; Arteriosclerosis; Cardiotonic Agents; Cognition; Female; Humans; Macaca fascicularis; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2002 |
Tamoxifen, raloxifene and the prevention of breast cancer.
Topics: Adult; Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Coronary Disease; Drug Design; Endometrial Neoplasms; Estrogens; Female; Humans; Incidence; Mammary Neoplasms, Experimental; Middle Aged; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Osteoporosis; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Tamoxifen | 2002 |
[Advancement of treatment for osteoporosis].
Topics: Alendronate; Bone Density; Cholecalciferol; Clinical Trials as Topic; Estrogen Replacement Therapy; Etidronic Acid; Fractures, Bone; Humans; Hydroxycholecalciferols; Osteoporosis; Raloxifene Hydrochloride; Vitamin K 2 | 2002 |
[Treatment of osteoporosis: overview].
Topics: Bone Density; Clinical Trials as Topic; Diphosphonates; Estrogen Replacement Therapy; Evidence-Based Medicine; Femoral Neck Fractures; Fractures, Stress; Humans; Osteoporosis; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Spinal Fractures | 2002 |
[Comparative analyses on osteoporosis guidelines in Japan, EU and USA].
Topics: Alendronate; Calcitonin; Clinical Trials as Topic; Drug Approval; Estriol; Etidronic Acid; Europe; Humans; Isoflavones; Japan; Osteoporosis; Practice Guidelines as Topic; Raloxifene Hydrochloride; United States; Vitamin K 2 | 2002 |
The search for the ideal SERM.
Topics: Animals; Cardiovascular Diseases; Clinical Trials as Topic; Cognition; Estrogens; Female; Humans; Neoplasms, Hormone-Dependent; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen | 2002 |
[Antiestrogen therapy in the treatment of breast neoplasms].
Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Estrogen Antagonists; Female; Forecasting; Humans; Indoles; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene; Triazoles | 2002 |
32 trial(s) available for raloxifene hydrochloride and Osteoporosis
| Article | Year |
|---|---|
Effect of Bone Resorption Inhibitors on Serum Cholesterol Level and Fracture Risk in Osteoporosis: Randomized Comparative Study Between Minodronic Acid and Raloxifene.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Cholesterol; Female; Fractures, Bone; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Prospective Studies; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures | 2023 |
Raloxifene Prevents Early Periprosthetic Bone Loss for Postmenopausal Women after Uncemented Total Hip Arthroplasty: A Randomized Placebo-Controlled Clinical Trial.
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Bone Density Conservation Agents; Bone Resorption; Disability Evaluation; Double-Blind Method; Female; Humans; Middle Aged; Osteoporosis; Postmenopause; Postoperative Complications; Prospective Studies; Quality of Life; Raloxifene Hydrochloride | 2020 |
Risk factors for incident vertebral fractures in osteoporosis pharmacotherapy: a 2-year, prospective, observational study.
Topics: Accidental Falls; Aged; Biomarkers; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Multivariate Analysis; Osteoporosis; Prevalence; Prospective Studies; Raloxifene Hydrochloride; Risk Factors; Spinal Fractures | 2021 |
Incidence of osteonecrosis of the jaw in Japanese osteoporosis patients taking minodronic acid.
Topics: Administration, Oral; Asian People; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Female; Humans; Incidence; Japan; Male; Middle Aged; Oral Health; Osteoporosis; Raloxifene Hydrochloride; Risk Factors; Surveys and Questionnaires | 2019 |
Inverse correlation of carotid intima-media thickness with raloxifene serum levels in osteoporosis.
Topics: Adult; Aged; Biomarkers; Carotid Artery Diseases; E-Selectin; Female; Humans; Intercellular Adhesion Molecule-1; Middle Aged; Osteoporosis; Prospective Studies; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Slovenia; Statistics as Topic; Tunica Intima; Tunica Media; Vascular Cell Adhesion Molecule-1 | 2014 |
Psychometric properties of the osteoporosis assessment questionnaire (OPAQ) 2.0: results from the multiple outcomes of raloxifene evaluation (MORE) study.
Topics: Aged; Bone Density Conservation Agents; Female; Humans; Middle Aged; Osteoporosis; Psychometrics; Raloxifene Hydrochloride; Retrospective Studies; Surveys and Questionnaires; Treatment Outcome | 2014 |
Preventive effects of raloxifene treatment on agerelated weight loss in postmenopausal women.
Topics: Aged; Biomarkers; Body Mass Index; Female; Follow-Up Studies; Humans; Middle Aged; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Retrospective Studies; Weight Loss | 2017 |
Effect of osteoporosis medication on changes in bone mineral density and bone turnover markers after 24-month administration of daily teriparatide: comparison among minodronate, raloxifene, and eldecalcitol.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Middle Aged; Osteogenesis; Osteoporosis; Raloxifene Hydrochloride; Tartrate-Resistant Acid Phosphatase; Teriparatide; Vitamin D | 2018 |
Benefits and risks of raloxifene by vertebral fracture status.
Topics: Aged; Bone Density Conservation Agents; Double-Blind Method; Female; Humans; Incidence; Middle Aged; Osteoporosis; Placebos; Raloxifene Hydrochloride; Spinal Fractures; Treatment Outcome | 2010 |
XbaI polymorphism of the estrogen receptor alpha gene influences the effect of raloxifene on the endothelial function.
Topics: Aged; E-Selectin; Endothelium, Vascular; Estrogen Receptor alpha; Female; Humans; Intercellular Adhesion Molecule-1; Middle Aged; Osteoporosis; Polymorphism, Genetic; Prospective Studies; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Vascular Diseases; Vasodilation | 2010 |
The effects of selective estrogen receptor modulator treatment following hormone replacement therapy on elderly postmenopausal women with osteoporosis.
Topics: Adiponectin; Aged; Blood Glucose; Bone Density; Cholesterol, HDL; Cholesterol, LDL; Estriol; Estrogen Replacement Therapy; Female; Humans; Japan; Medroxyprogesterone; Nitric Oxide; Osteoporosis; Postmenopause; Prospective Studies; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tumor Necrosis Factor-alpha | 2011 |
The hemorheological effects of raloxifene in postmenopausal women with osteoporosis. Results of a 3-year placebo-controlled clinical trial.
Topics: Aged; Blood Viscosity; Estrogen Antagonists; Female; Fibrinogen; Hemorheology; Humans; Middle Aged; Osteoporosis; Placebos; Postmenopause; Prospective Studies; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Stress, Mechanical; Treatment Outcome | 2002 |
Raloxifene administration in women treated with gonadotropin-releasing hormone agonist for uterine leiomyomas: effects on bone metabolism.
Topics: Adult; Body Mass Index; Bone and Bones; Bone Density; Calcium; Delayed-Action Preparations; Female; Femur; Humans; Leiomyoma; Leuprolide; Lumbar Vertebrae; Middle Aged; Osteoporosis; Phosphorus; Placebos; Premenopause; Prospective Studies; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Uterine Neoplasms | 2002 |
Efficacy and safety of raloxifene 60 milligrams/day in postmenopausal Asian women.
Topics: Asian People; Bone Density; Cholesterol, HDL; Cholesterol, LDL; Estrogen Antagonists; Female; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Triglycerides | 2003 |
Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk.
Topics: Aged; Biomarkers; Bone Density; Bone Remodeling; Female; Femur Neck; Humans; Middle Aged; Osteoporosis; Prevalence; Radiography; Raloxifene Hydrochloride; Risk Factors; Spinal Fractures | 2004 |
Effect of raloxifene on lowering lipid parameters in patients with osteoporosis.
Topics: Aged; Bone Density; Cholesterol; Female; Humans; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Triglycerides | 2003 |
Effect of raloxifene on the incidence of elevated low density lipoprotein (LDL) and achievement of LDL target goals in postmenopausal women.
Topics: Aged; Cholesterol, LDL; Female; Humans; Incidence; Middle Aged; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Treatment Outcome | 2004 |
Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial.
Topics: Aged; Biomarkers; Bone Density; Bone Remodeling; Double-Blind Method; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Osteoporosis; Prostatic Neoplasms; Pulmonary Embolism; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Testosterone | 2004 |
Vitamin D insufficiency does not affect bone mineral density response to raloxifene.
Topics: Aged; Bone Density; Drug Interactions; Estrogen Antagonists; Humans; Incidence; Middle Aged; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Spinal Fractures; Vitamin D; Vitamin D Deficiency | 2005 |
Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene.
Topics: Aged; Bone Density; Bone Resorption; Carrier Proteins; Collagen; Collagen Type I; Estrogens; Female; Gene Expression Regulation; Glycoproteins; Hormone Replacement Therapy; Humans; Leukocytes, Mononuclear; Longitudinal Studies; Membrane Glycoproteins; Middle Aged; Osteoporosis; Osteoprotegerin; Peptides; Postmenopause; Raloxifene Hydrochloride; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; RNA, Messenger; Selective Estrogen Receptor Modulators | 2005 |
Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.
Topics: Aged; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Breast Neoplasms; Double-Blind Method; Female; Femoral Neck Fractures; Femur Neck; Fracture Healing; Fractures, Bone; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Placebos; Poisson Distribution; Postmenopause; Proportional Hazards Models; Raloxifene Hydrochloride; Risk; Time Factors; Treatment Outcome | 2005 |
Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
Topics: Aged; Biomarkers; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Bone Remodeling; Double-Blind Method; Female; Humans; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Polymorphism, Genetic; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Women | 2006 |
Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.
Topics: Bone Density; Bone Density Conservation Agents; Collagen Type I; Drug Combinations; Estradiol; Estrogen Replacement Therapy; Female; Humans; Norethindrone; Osteocalcin; Osteoporosis; Peptides; Postmenopause; Raloxifene Hydrochloride | 2007 |
Cognitive effects of short-term use of raloxifene: a randomized clinical trial.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cognition; Educational Status; Female; Humans; Middle Aged; Neuropsychological Tests; Osteoporosis; Postmenopause; Raloxifene Hydrochloride | 2007 |
Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis.
Topics: Aged; Alendronate; Biomarkers; Bone Density; Calcium; Female; Fractures, Bone; Humans; Lipid Metabolism; Osteoporosis; Phosphorus; Raloxifene Hydrochloride; Spine | 2008 |
Drugs can reduce the incidence of breast cancer: now what?
Topics: Adult; Aged; Breast Neoplasms; Female; Humans; Middle Aged; Osteoporosis; Postmenopause; Premenopause; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Uterine Neoplasms | 1999 |
Does raloxifene reduce postmenopausal women's risk of breast cancer?
Topics: Adult; Aged; Breast Neoplasms; Double-Blind Method; Estrogen Antagonists; Family Practice; Female; Humans; Middle Aged; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Risk Assessment | 2000 |
Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Double-Blind Method; Estrogens; Female; Humans; Incidence; Middle Aged; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Risk; Risk Factors; Selective Estrogen Receptor Modulators; Treatment Outcome | 2001 |
Influence of smoking on the antiosteoporotic efficacy of raloxifene.
Topics: Biomarkers; Bone and Bones; Bone Density; Female; Follow-Up Studies; Fractures, Bone; Hormones; Humans; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Smoking | 2001 |
Effect of raloxifene on serum triglycerides in postmenopausal women: influence of predisposing factors for hypertriglyceridemia.
Topics: Adult; Aged; Aged, 80 and over; Causality; Female; Humans; Hypertriglyceridemia; Middle Aged; Osteoporosis; Pancreatitis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Thiophenes; Triglycerides | 2001 |
Role of tumor necrosis factor-alpha and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women.
Topics: Analysis of Variance; C-Reactive Protein; Cardiovascular Diseases; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Estrogen Antagonists; Female; Hormone Replacement Therapy; Humans; Interleukin-6; Middle Aged; Osteoporosis; Postmenopause; Prospective Studies; Raloxifene Hydrochloride; Risk Factors; Tumor Necrosis Factor-alpha | 2001 |
Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men.
Topics: Aged; Biomarkers; Bone Remodeling; Bone Resorption; Collagen; Collagen Type I; Estradiol; Follicle Stimulating Hormone; Gonadal Steroid Hormones; Humans; Lipids; Luteinizing Hormone; Male; Middle Aged; Osteoporosis; Parathyroid Hormone; Peptides; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2001 |
165 other study(ies) available for raloxifene hydrochloride and Osteoporosis
| Article | Year |
|---|---|
Patterns of Osteoporosis Medications Selection After Drug Holiday or Continued Therapy: A Real-World Experience.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Retrospective Studies; Teriparatide; United States; Zoledronic Acid | 2022 |
Treatment patterns of long-dose-interval medication for persistent management of osteoporosis in Taiwan.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Female; Humans; Ibandronic Acid; Male; Medication Adherence; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Taiwan; Teriparatide; Zoledronic Acid | 2022 |
Raloxifene increases the risk of gastroesophageal reflux disease, Barrett's esophagus, and esophageal stricture in postmenopausal women with osteoporosis.
Topics: Barrett Esophagus; Case-Control Studies; Cohort Studies; Esophageal Stenosis; Female; Gastroesophageal Reflux; Humans; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Risk Factors | 2023 |
Osteoporosis management in Australian general practice: an analysis of current osteoporosis treatment patterns and gaps in practice.
Topics: Aged; Aged, 80 and over; Attitude of Health Personnel; Australia; Bone Density Conservation Agents; Denosumab; Deprescriptions; Diphosphonates; Drug Substitution; Female; General Practice; General Practitioners; Humans; Longitudinal Studies; Male; Middle Aged; Norpregnenes; Osteoporosis; Osteoporotic Fractures; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Retrospective Studies; Teriparatide; Thiophenes | 2020 |
Effect of pre-treatment of strength training and raloxifene in periestropause on bone healing.
Topics: Animals; Bony Callus; Female; Fracture Healing; Humans; Osteoporosis; Raloxifene Hydrochloride; Rats; Rats, Wistar; Resistance Training | 2020 |
Physically Optimized Nano-Lipid Carriers Augment Raloxifene and Vitamin D Oral Bioavailability in Healthy Humans for Management of Osteoporosis.
Topics: Biological Availability; Drug Carriers; Humans; Lipids; Osteoporosis; Raloxifene Hydrochloride; Vitamin D; Vitamins | 2020 |
Osteoporosis Management in the Era of COVID-19.
Topics: Absorptiometry, Photon; Biomarkers; Bone Density; Bone Density Conservation Agents; Continuity of Patient Care; Coronavirus Infections; COVID-19; Denosumab; Disease Management; Drug Administration Schedule; Estrogen Replacement Therapy; Fractures, Spontaneous; Home Care Services; Humans; Immunosuppression Therapy; Osteoporosis; Pandemics; Pneumonia, Viral; Raloxifene Hydrochloride; Recurrence; Telemedicine; Thrombophilia; Unnecessary Procedures | 2020 |
Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Female; Follow-Up Studies; Humans; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Treatment Outcome | 2020 |
Raloxifene inhibits the overexpression of TGF-β1 in cartilage and regulates the metabolism of subchondral bone in rats with osteoporotic osteoarthritis.
Topics: Animals; Bone Remodeling; Cartilage, Articular; Female; Osteoarthritis; Osteoporosis; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Transforming Growth Factor beta1; X-Ray Microtomography | 2021 |
Raloxifene retards the progression of adjacent segmental intervertebral disc degeneration by inhibiting apoptosis of nucleus pulposus in ovariectomized rats.
Topics: Animals; Apoptosis; Bone Density; Disease Models, Animal; Disease Progression; Female; Intervertebral Disc Degeneration; Lumbar Vertebrae; Nucleus Pulposus; Osteoporosis; Ovariectomy; Postoperative Complications; Raloxifene Hydrochloride; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Spinal Fusion | 2021 |
Raloxifene but not alendronate can compensate the impaired osseointegration in osteoporotic rats.
Topics: Alendronate; Animals; Bone Density; Dental Implants; Disease Models, Animal; Female; Immunoenzyme Techniques; Implants, Experimental; Microscopy, Confocal; Osseointegration; Osteoporosis; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Tibia; X-Ray Microtomography | 2018 |
Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians.
Topics: Bone Diseases, Metabolic; Calcium, Dietary; Denosumab; Diphosphonates; Estrogen Replacement Therapy; Exercise; Female; Fractures, Bone; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Teriparatide; Vitamin D | 2017 |
Improving Combination Osteoporosis Therapy in a Preclinical Model of Heightened Osteoanabolism.
Topics: Animals; Bone and Bones; Bone Resorption; Diphosphonates; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Imidazoles; Mice; Mice, Knockout; Nuclear Matrix-Associated Proteins; Osteoporosis; Parathyroid Hormone; Raloxifene Hydrochloride; Transcription Factors; Zoledronic Acid | 2017 |
Effects of combination treatment with alendronate and raloxifene on skeletal properties in a beagle dog model.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diaphyses; Dogs; Drug Therapy, Combination; Female; Femur; Lumbar Vertebrae; Magnetic Resonance Imaging; Models, Animal; Osteoporosis; Raloxifene Hydrochloride | 2017 |
Effects of strength training and raloxifene on femoral neck metabolism and microarchitecture of aging female Wistar rats.
Topics: Aging; Animals; Bone Density; Bone Density Conservation Agents; Combined Modality Therapy; Female; Femur Neck; Osteoblasts; Osteoclasts; Osteoporosis; Phosphates; Raloxifene Hydrochloride; Random Allocation; Rats, Wistar; Resistance Training; Tartrate-Resistant Acid Phosphatase | 2017 |
Poly(methyl vinyl ether-co-maleic acid) for enhancement of solubility, oral bioavailability and anti-osteoporotic effects of raloxifene hydrochloride.
Topics: Administration, Oral; Alkaline Phosphatase; Animals; Biological Availability; Bone Density Conservation Agents; Calcium; Female; Maleates; Microscopy, Electron, Scanning; Nanoparticles; Osteoporosis; Ovariectomy; Phosphorus; Polyethylenes; Raloxifene Hydrochloride; Rats, Wistar; Solubility; Technology, Pharmaceutical | 2018 |
Mandibular Osteonecrosis Associated With Raloxifene.
Topics: Bone Density Conservation Agents; Female; Humans; Mandibular Diseases; Middle Aged; Osteonecrosis; Osteoporosis; Raloxifene Hydrochloride | 2018 |
Enhanced solubility, oral bioavailability and anti-osteoporotic effects of raloxifene HCl in ovariectomized rats by Igepal CO-890 nanomicelles.
Topics: Administration, Oral; Animals; Biological Availability; Caco-2 Cells; Female; Humans; Micelles; Nanoparticles; Osteoporosis; Ovariectomy; Particle Size; Raloxifene Hydrochloride; Rats; Rats, Wistar; Solubility | 2019 |
The influence of alendronate and tooth extraction on the incidence of osteonecrosis of the jaw among osteoporotic subjects.
Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Female; Humans; Logistic Models; Male; Middle Aged; Odds Ratio; Osteoporosis; Prevalence; Raloxifene Hydrochloride; Retrospective Studies; Tooth Extraction | 2018 |
A SERM increasing the expression of the osteoblastogenesis and mineralization-related proteins and improving quality of bone tissue in an experimental model of osteoporosis.
Topics: Animals; beta Catenin; Core Binding Factor Alpha 1 Subunit; Disease Models, Animal; Female; Gene Expression; Immunohistochemistry; Osteoblasts; Osteocalcin; Osteogenesis; Osteopontin; Osteoporosis; Ovariectomy; Polymerase Chain Reaction; Proteins; Raloxifene Hydrochloride; Rats, Wistar; Reference Values; Reproducibility of Results; Selective Estrogen Receptor Modulators; Time Factors; Treatment Outcome; Wnt Proteins; X-Ray Microtomography | 2018 |
Design of a transdermal formulation containing raloxifene nanoparticles for osteoporosis treatment.
Topics: Administration, Cutaneous; Animals; Biological Availability; Body Weight; Calcium; Chemistry, Pharmaceutical; Drug Delivery Systems; Drug Liberation; Endocytosis; Male; Menthol; Nanoparticles; Osteoporosis; Ovariectomy; Particle Size; Raloxifene Hydrochloride; Rats, Wistar; Skin Absorption; Solubility | 2018 |
The estrogen receptor 1 gene affects bone mineral density and osteoporosis treatment efficiency in Slovak postmenopausal women.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Estradiol; Estrogen Receptor alpha; Estrogen Replacement Therapy; Female; Femur Neck; Fractures, Bone; Gene Expression; Genotype; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis; Polymorphism, Single Nucleotide; Postmenopause; Progesterone; Raloxifene Hydrochloride; Slovakia; Treatment Outcome | 2018 |
Changes in bone mineral density (BMD): a longitudinal study of osteoporosis patients in the real-world setting.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Femur Neck; Humans; Longitudinal Studies; Male; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Teriparatide; Time Factors; Treatment Outcome | 2018 |
The importance of inhibition of a catabolic pathway of methotrexate metabolism in its efficacy for rheumatoid arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Drug Therapy, Combination; Female; Folic Acid; Folic Acid Antagonists; Humans; Leucovorin; Male; Methotrexate; Osteoporosis; Purines; Raloxifene Hydrochloride; Rats; Rats, Inbred Lew; Treatment Outcome | 2019 |
Investigation of in vitro permeability and in vivo pharmacokinetic behavior of bare and functionalized MCM-41 and MCM-48 mesoporous silica nanoparticles: a burst and controlled drug release system for raloxifene.
Topics: Administration, Oral; Animals; Biological Availability; Breast Neoplasms; Caco-2 Cells; Chemical Engineering; Delayed-Action Preparations; Drug Carriers; Drug Liberation; Drug Screening Assays, Antitumor; Estrogen Antagonists; Female; Humans; Intestinal Mucosa; Mice; Nanoparticles; Osteoporosis; Permeability; Raloxifene Hydrochloride; Silicon Dioxide | 2019 |
Combined administration on You-Gui Yin and low-dose Raloxifene partially attenuates the bone loss in ovariectomized mice through the proliferation and osteogenic differentiation of bone marrow stromal cells.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Resorption; Cell Differentiation; Cell Proliferation; Disease Models, Animal; Drug Synergism; Drugs, Chinese Herbal; Female; Mesenchymal Stem Cells; Mice, Inbred C57BL; Osteogenesis; Osteoporosis; Ovariectomy; Raloxifene Hydrochloride; Tibia | 2019 |
Differences in adherence to osteoporosis regimens: a 2-year analysis of a population treated under specific guidelines.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcitonin; Female; Humans; Male; Medication Adherence; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Risk Factors; Young Adult | 2013 |
In vivo reference point indentation reveals positive effects of raloxifene on mechanical properties following 6 months of treatment in skeletally mature beagle dogs.
Topics: Animals; Bone Density Conservation Agents; Bone Remodeling; Disease Models, Animal; Dogs; Female; Osteoporosis; Raloxifene Hydrochloride | 2013 |
Effect of anti-osteoporotic agents on the prevention of bone loss in unloaded bone.
Topics: Animals; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Drug Evaluation, Preclinical; Female; Femur; Hindlimb Suspension; Male; Osteoporosis; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Tibia; Weightlessness; Weightlessness Simulation | 2013 |
Substantial under-treatment among women diagnosed with osteoporosis in a US managed-care population: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Managed Care Programs; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Risedronic Acid; Teriparatide; United States; Zoledronic Acid | 2014 |
Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population.
Topics: Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Calcitonin; Female; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Raloxifene Hydrochloride; Retrospective Studies; Risk Assessment; Taiwan | 2014 |
Incidence and risk of venous thromboembolism among Taiwan osteoporotic fracture population under osteoporosis pharmacological treatments.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcitonin; Female; Humans; Incidence; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Raloxifene Hydrochloride; Retrospective Studies; Risk; Taiwan; Venous Thromboembolism | 2014 |
Effects of sequential osteoporosis treatments on trabecular bone in adult rats with low bone mass.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Femur; Hormone Replacement Therapy; Lumbar Vertebrae; Osteoporosis; Osteoporotic Fractures; Ovariectomy; Parathyroid Hormone; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Stress, Mechanical; Weight-Bearing; X-Ray Microtomography | 2014 |
The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Female; Humans; Male; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Risk Factors; Taiwan | 2014 |
Evaluation of the prescription of osteoporosis treatment after a major osteoporotic fracture.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Calcium; Dietary Supplements; Diphosphonates; Female; Follow-Up Studies; Fractures, Bone; France; Hip Fractures; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Prescriptions; Raloxifene Hydrochloride; Retrospective Studies; Thiophenes; Treatment Outcome; Vitamin D; Wrist Injuries; Zoledronic Acid | 2014 |
Osteoporosis drugs: which one is right for you? There's no one-size-fits-all answer. Understanding your options begins with knowing what's available.
Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcitonin; Denosumab; Female; Fractures, Spontaneous; Health Knowledge, Attitudes, Practice; Humans; Osteoporosis; Raloxifene Hydrochloride; Women's Health | 2014 |
Back pain in patients with severe osteoporosis on teriparatide or antiresorptives: a prospective observational study in a multiethnic population.
Topics: Aged; Back Pain; Bone Density Conservation Agents; Diphosphonates; Ethnicity; Female; Humans; International Cooperation; Male; Middle Aged; Osteoporosis; Prospective Studies; Quality of Life; Raloxifene Hydrochloride; Surveys and Questionnaires; Teriparatide; Time Factors; Treatment Outcome | 2014 |
Efficacy, effectiveness and side effects of medications used to prevent fractures.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium Compounds; Denosumab; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Hip Fractures; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Osteoporotic Fractures; Raloxifene Hydrochloride; Risedronic Acid; Risk Assessment; Spinal Fractures; Teriparatide; Thiophenes; Treatment Outcome; Vitamin D; Zoledronic Acid | 2015 |
Raloxifene enhances peri-implant bone healing in osteoporotic rats.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Dental Implants; Female; Implants, Experimental; Microscopy, Confocal; Osteoporosis; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Wistar; Tibia | 2015 |
Alveolar bone dynamics in osteoporotic rats treated with raloxifene or alendronate: confocal microscopy analysis.
Topics: Alendronate; Alveolar Process; Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Female; Microscopy, Confocal; Osteoporosis; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Rats, Wistar | 2015 |
Comparison of the prescribing pattern of bisphosphonate and raloxifene in Korean women with osteoporosis: from a national health insurance claims database.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Databases, Factual; Diphosphonates; Drug Administration Schedule; Drug Prescriptions; Female; Humans; Insurance, Health; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Seoul | 2015 |
Use of anti-osteoporotic drugs in central Norway after a forearm fracture.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Denosumab; Diphosphonates; Drug Prescriptions; Female; Forearm; Forearm Injuries; Fractures, Bone; Glucocorticoids; Humans; Male; Middle Aged; Norway; Osteoporosis; Patient Compliance; Raloxifene Hydrochloride; Secondary Prevention; Teriparatide | 2015 |
Bone strength: more than just bone density.
Topics: Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Humans; Osteoporosis; Raloxifene Hydrochloride | 2016 |
Proportion and Characteristics of Patients in Sweden Remaining at High Risk of Fracture Despite Prior Treatment.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Estrogen Antagonists; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Risk; Sweden | 2016 |
Fracture risk and healthcare resource utilization and costs among osteoporosis patients with type 2 diabetes mellitus and without diabetes mellitus in Japan: retrospective analysis of a hospital claims database.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Comorbidity; Diabetes Mellitus, Type 2; Female; Health Care Costs; Humans; Incidence; Japan; Middle Aged; Osteoporosis; Osteoporotic Fractures; Patient Acceptance of Health Care; Prevalence; Raloxifene Hydrochloride; Retrospective Studies; Risk Factors | 2016 |
Selective estrogen receptor modulators and the vitamin D analogue eldecalcitol block bone loss in male osteoporosis.
Topics: Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Indoles; Male; Mice; Mice, Inbred C57BL; Orchiectomy; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Testosterone; Vitamin D | 2017 |
Extracorporeal shock waves alone or combined with raloxifene promote bone formation and suppress resorption in ovariectomized rats.
Topics: Adiponectin; Animals; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Resorption; Disease Models, Animal; Female; High-Energy Shock Waves; Osteogenesis; Osteoporosis; Ovariectomy; PPAR gamma; Raloxifene Hydrochloride; Rats; Transcription, Genetic | 2017 |
Review of comparative effectiveness of treatments to prevent fractures.
Topics: Bone Density Conservation Agents; Cardiovascular Diseases; Clinical Trials as Topic; Fractures, Bone; Humans; Osteoporosis; Raloxifene Hydrochloride | 2008 |
Effects of genistein aglycone in osteoporotic, ovariectomized rats: a comparison with alendronate, raloxifene and oestradiol.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Estradiol; Female; Genistein; Osteoporosis; Ovariectomy; Phytoestrogens; Raloxifene Hydrochloride; Random Allocation; Rats; Rats, Sprague-Dawley; Time Factors | 2008 |
[Treatment of osteoporosis in the elderly: what is the evidence?].
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Alendronate; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Teriparatide; Treatment Outcome | 2008 |
Estrogen and raloxifene improve metaphyseal fracture healing in the early phase of osteoporosis. A new fracture-healing model at the tibia in rat.
Topics: Analysis of Variance; Animals; Biomechanical Phenomena; Bone Density Conservation Agents; Disease Models, Animal; Drug Therapy, Combination; Estradiol; Female; Fluorescent Dyes; Fracture Fixation, Internal; Fracture Healing; Microradiography; Osteoporosis; Osteotomy; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Tibial Fractures | 2010 |
Effect of testosterone, raloxifene and estrogen replacement on the microstructure and biomechanics of metaphyseal osteoporotic bones in orchiectomized male rats.
Topics: Administration, Oral; Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Bone Resorption; Disease Models, Animal; Estrogens; Hormone Replacement Therapy; Male; Orchiectomy; Osteoporosis; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Testosterone | 2009 |
Propensity score estimation with missing values using a multiple imputation missingness pattern (MIMP) approach.
Topics: Bias; Biometry; Bone Density; Bone Density Conservation Agents; Causality; Computer Simulation; Data Interpretation, Statistical; Female; Humans; Models, Statistical; Osteoporosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic | 2009 |
Comparative effects of risedronate, atorvastatin, estrogen and SERMs on bone mass and strength in ovariectomized rats.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Bone Density; Bone Density Conservation Agents; Clomiphene; Estrogens; Etidronic Acid; Female; Femur; Heptanoic Acids; Osteoporosis; Ovariectomy; Pyrroles; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Risedronic Acid; Selective Estrogen Receptor Modulators; Tibia | 2009 |
More on reports of esophageal cancer with oral bisphosphonate use.
Topics: Administration, Oral; Bone Density Conservation Agents; Calcitonin; Diphosphonates; Esophageal Neoplasms; Humans; Incidence; Osteoporosis; Raloxifene Hydrochloride; SEER Program; United States | 2009 |
[Economics of medicament therapies for osteoporosis].
Topics: Bone Density Conservation Agents; Drug Costs; Femoral Neck Fractures; Humans; Hydroxycholecalciferols; Japan; Low Back Pain; Osteoporosis; Protective Devices; Raloxifene Hydrochloride | 2009 |
Raloxifene ameliorates detrimental enzymatic and nonenzymatic collagen cross-links and bone strength in rabbits with hyperhomocysteinemia.
Topics: Animals; Arginine; Bone and Bones; Bone Density; Bone Density Conservation Agents; Collagen; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Glycation End Products, Advanced; Hyperhomocysteinemia; Lysine; Methionine; Osteoporosis; Rabbits; Raloxifene Hydrochloride; Stress, Mechanical | 2010 |
[4/5. Osteoporosis].
Topics: Administration, Oral; Adult; Bone Density Conservation Agents; Calcium; Fractures, Bone; Humans; Menopause; Middle Aged; Osteoporosis; Raloxifene Hydrochloride | 2009 |
Use of bisphosphonates and raloxifene and risk of deep venous thromboembolism and pulmonary embolism.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Denmark; Diphosphonates; Dose-Response Relationship, Drug; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Organometallic Compounds; Osteoporosis; Pulmonary Embolism; Raloxifene Hydrochloride; Thiophenes; Venous Thromboembolism | 2010 |
Gastric and esophagus events before and during treatment of osteoporosis.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Case-Control Studies; Causality; Clodronic Acid; Cohort Studies; Denmark; Diphosphonates; Esophageal Perforation; Etidronic Acid; Female; Gastrointestinal Tract; Humans; Iatrogenic Disease; Male; Middle Aged; Osteoporosis; Peptic Ulcer; Raloxifene Hydrochloride; Risk Assessment; Risk Factors | 2010 |
Effects of raloxifene on brachial arterial endothelial function, carotid wall thickness, and arterial stiffness in osteoporotic postmenopausal women.
Topics: Aged; Atherosclerosis; Blood Glucose; Blood Pressure; Bone Density; Brachial Artery; Carotid Arteries; Endothelium, Vascular; Estradiol; Female; Follicle Stimulating Hormone; Heart Rate; Humans; Lipids; Lumbar Vertebrae; Middle Aged; Osteoporosis; Pulse; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Vasodilation | 2010 |
Serum calcium, phosphorus and cardiovascular events in post-menopausal women.
Topics: Aged; Biomarkers; Bone Density Conservation Agents; Calcium; Cerebrovascular Disorders; Coronary Disease; Female; Follow-Up Studies; Humans; Incidence; Middle Aged; Multicenter Studies as Topic; Osteoporosis; Phosphorus; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors | 2011 |
Secondary prevention of osteoporosis in Australia: analysis of government-dispensed prescription data.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Australia; Bone Density Conservation Agents; Calcitriol; Calcium Carbonate; Calcium Citrate; Diphosphonates; Drug Administration Schedule; Drug Utilization; Female; Humans; Male; Osteoporosis; Raloxifene Hydrochloride; Sex Factors | 2010 |
Effects of raloxifene treatment on the structural geometry of the proximal femur in Japanese women with osteoporosis.
Topics: Absorptiometry, Photon; Asian People; Bone Density; Bone Density Conservation Agents; Female; Femur; Hip; Humans; Osteoporosis; Postmenopause; Raloxifene Hydrochloride | 2010 |
Stroke in relation to use of raloxifene and other drugs against osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Case-Control Studies; Denmark; Dose-Response Relationship, Drug; Drug Administration Schedule; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Risk Assessment; Stroke | 2011 |
Persistence to medical treatment of osteoporosis in women at three different clinical settings--a historical cohort study.
Topics: Adult; Aged; Bone Density Conservation Agents; Cohort Studies; Denmark; Diphosphonates; Educational Status; Female; Follow-Up Studies; Humans; Medication Adherence; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Patient Education as Topic; Raloxifene Hydrochloride; Surveys and Questionnaires | 2010 |
Adjustment for the measurement error in evaluating biomarkers.
Topics: Biomarkers; Bone Density; Bone Density Conservation Agents; Computer Simulation; Data Interpretation, Statistical; Evaluation Studies as Topic; Female; Fractures, Bone; Humans; Models, Statistical; Osteoporosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Reproducibility of Results | 2010 |
Effects of the combination treatment of raloxifene and alendronate on the biomechanical properties of vertebral bone.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Densitometry; Drug Therapy, Combination; Humans; Lumbar Vertebrae; Models, Statistical; Osteoporosis; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley | 2011 |
Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Case-Control Studies; Denmark; Diphosphonates; Female; Femoral Fractures; Hip Fractures; Humans; Male; Middle Aged; Organometallic Compounds; Osteoporosis; Raloxifene Hydrochloride; Risk Factors; Thiophenes | 2011 |
Prospective evaluation of Vitamin K2, Raloxifene and their co-administration in osteoporotic rats.
Topics: Animals; Blood Chemical Analysis; Bone Density; Drug Therapy, Combination; Female; Femur; Osteoporosis; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Wistar; Tibia; Uterus; Vitamin K 2 | 2011 |
Combined treatment with dexamethasone and raloxifene totally abrogates osteoporosis and joint destruction in experimental postmenopausal arthritis.
Topics: Animals; Arthritis, Experimental; B-Lymphocytes; Bone Density; Bone Marrow; Dexamethasone; Drug Therapy, Combination; Estradiol; Estrogens; Female; Glucocorticoids; Joints; Mice; Mice, Inbred DBA; Osteoporosis; Ovariectomy; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; T-Lymphocytes | 2011 |
Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Drug Substitution; Drug-Related Side Effects and Adverse Reactions; Etidronic Acid; Female; Gastrointestinal Diseases; Gastrointestinal Tract; Humans; Male; Medication Adherence; Middle Aged; Organometallic Compounds; Osteoporosis; Raloxifene Hydrochloride; Registries; Retrospective Studies; Risedronic Acid; Sweden; Thiophenes | 2011 |
Oral bisphosphonate use increases the risk for inflammatory jaw disease: a cohort study.
Topics: Administration, Oral; Aged; Alcoholism; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Case-Control Studies; Cohort Studies; Denmark; Diabetes Complications; Diphosphonates; Drug Therapy; Etidronic Acid; Female; Humans; Jaw Diseases; Male; Neoplasms; Organometallic Compounds; Osteitis; Osteomyelitis; Osteoporosis; Parathyroid Hormone; Periostitis; Radiotherapy; Raloxifene Hydrochloride; Risk Factors; Sjogren's Syndrome; Strontium; Thiophenes | 2012 |
Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cardiovascular Diseases; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Osteoporosis; Proportional Hazards Models; Raloxifene Hydrochloride; Retrospective Studies; Risk; Taiwan | 2011 |
Acute myocardial infarction and atherosclerosis of the coronary arteries in patients treated with drugs against osteoporosis: calcium in the vessels and not the bones?
Topics: Aged; Alendronate; Atherosclerosis; Bone Density Conservation Agents; Calcium; Cohort Studies; Diphosphonates; Etidronic Acid; Female; Humans; Male; Middle Aged; Myocardial Infarction; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies | 2012 |
[A case of non-alcoholic fatty liver disease (NAFLD) aggravated after treatment with raloxifene].
Topics: Aged; Fatty Liver; Female; Humans; Non-alcoholic Fatty Liver Disease; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2011 |
Low-energy diaphyseal femoral fractures associated with bisphosphonate use and severe curved femur: a case series.
Topics: Age Factors; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Plates; Diaphyses; Diphosphonates; Female; Femoral Fractures; Femur; Humans; Male; Osteoporosis; Radiography; Raloxifene Hydrochloride; Retrospective Studies | 2012 |
Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Chemoprevention; Drug Utilization; Female; Humans; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Tamoxifen; United States | 2012 |
Influence of hepatic and intestinal efflux transporters and their genetic variants on the pharmacokinetics and pharmacodynamics of raloxifene in osteoporosis treatment.
Topics: Bone Density Conservation Agents; Caco-2 Cells; Carrier Proteins; Cell Membrane; Chromatography, Liquid; Female; Gene Expression Regulation; Genetic Variation; Genotype; Humans; Intestinal Mucosa; Liver; Membranes, Artificial; Multidrug Resistance-Associated Protein 2; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Tandem Mass Spectrometry | 2012 |
Modulation of bone turnover in orchidectomized rats treated with raloxifene and risedronate.
Topics: Administration, Oral; Animals; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calcium; Cathepsin K; Cell Count; Drug Therapy, Combination; Etidronic Acid; Injections, Subcutaneous; Male; Orchiectomy; Osteoclasts; Osteocytes; Osteoporosis; Radiography; Raloxifene Hydrochloride; Random Allocation; Rats; Rats, Wistar; Risedronic Acid | 2013 |
My doctor wanted me to start taking Evista (raloxifene hydrochloride) for osteoporosis, but I'm worried because the drug is linked to a risk of blood clots. I have mild hypertension that I manage with medications, diet and exercise. Do you think the drug
Topics: Bone Density Conservation Agents; Diet; Exercise; Female; Humans; Hypertension; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Stroke; Thrombosis | 2010 |
Variations in nanomechanical properties and tissue composition within trabeculae from an ovine model of osteoporosis and treatment.
Topics: Animals; Biomechanical Phenomena; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Imidazoles; Nanotechnology; Osteoporosis; Raloxifene Hydrochloride; Sheep; Spectrum Analysis, Raman; Zoledronic Acid | 2013 |
Treatment of osteoporosis and hip fractures in a Spanish health area.
Topics: Bone Density Conservation Agents; Diphosphonates; Hip Fractures; Humans; Longitudinal Studies; Organometallic Compounds; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Spain; Thiophenes | 2013 |
Raloxifene for the treatment and prevention of breast cancer?
Topics: Breast Neoplasms; Cardiovascular Diseases; Female; Humans; Lipids; Osteoporosis; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Uterus | 2001 |
[From effective to economical. The value of good osteoporosis therapy].
Topics: Calcium; Clinical Trials as Topic; Cost-Benefit Analysis; Diphosphonates; Female; Germany; Humans; Male; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Vitamin D | 2002 |
[CBO guideline 'Osteoporosis' (second revision].
Topics: Adrenal Cortex Hormones; Age Factors; Aged; Bone Density; Calcium, Dietary; Dietary Supplements; Female; Fractures, Bone; Humans; Male; Menopause; Middle Aged; Netherlands; Osteoporosis; Practice Guidelines as Topic; Prevalence; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Sex Factors; Societies, Medical; Vitamin D | 2002 |
Improvement in the undertreatment of osteoporosis following hip fracture.
Topics: Aged; Aged, 80 and over; Calcitonin; Calcium; Female; Femoral Neck Fractures; Hip Fractures; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; United States | 2002 |
[Patients with fractures are in the front line for osteoporosis treatment but how to treat?].
Topics: Alendronate; Bone Density; Calcitonin; Etidronic Acid; Fractures, Bone; Health Services Accessibility; Humans; Osteoporosis; Physician's Role; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors | 2001 |
[Do markers of bone metabolism reflect the presence of a high- or low-turnover state of bone metabolism?].
Topics: Absorptiometry, Photon; Biomarkers; Biopsy, Needle; Bone and Bones; Diphosphonates; Female; Humans; Male; Middle Aged; Osteoblasts; Osteoclasts; Osteoporosis; Parathyroid Hormone; Predictive Value of Tests; Raloxifene Hydrochloride | 2002 |
[Osteoporosis: diagnosis, prevention and treatment].
Topics: Adult; Aged; Calcitonin; Calcium Channel Blockers; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Injections, Intramuscular; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Selective Estrogen Receptor Modulators | 2002 |
[Weeks of pain, vertebral body fractures during sleep, invalidism. Save your osteoporosis patients from this fate].
Topics: Activities of Daily Living; Age Factors; Alendronate; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Disabled Persons; Etidronic Acid; Female; Femoral Fractures; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Pain; Raloxifene Hydrochloride; Risedronic Acid; Sex Factors; Spinal Fractures | 2002 |
Hip fracture patients are not treated for osteoporosis: a call to action.
Topics: Absorptiometry, Photon; Alendronate; Calcitonin; Calcium; Estrogen Antagonists; Estrogens; Hip Fractures; Humans; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Risk Factors; Treatment Failure; Vitamin D | 2002 |
[Diabetes, Conn syndrome and osteoporosis. What is new in diagnosis and therapy?].
Topics: Adenoma; Adrenal Gland Neoplasms; Adrenalectomy; Adult; Aged; Coronary Disease; Diabetes Mellitus, Type 2; Diphosphonates; Estrogen Antagonists; Female; Fractures, Bone; Humans; Hyperaldosteronism; Hyperglycemia; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators | 2003 |
[From alcohol abstinence to total surgery. Preventive strategies in breast carcinoma].
Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasms; Dietary Fats; Estradiol; Estrogen Antagonists; Ethanol; Follow-Up Studies; Humans; Incidence; Insulin-Like Growth Factor I; Mastectomy; Middle Aged; Obesity; Osteoporosis; Ovariectomy; Placebos; Postmenopause; Primary Prevention; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Sports; Tamoxifen; Time Factors | 2003 |
Early discontinuation of treatment for osteoporosis.
Topics: Alendronate; Bone Diseases, Metabolic; Breast Neoplasms; California; Cohort Studies; Estrogen Replacement Therapy; Female; Health Care Surveys; Health Knowledge, Attitudes, Practice; Heart Diseases; Humans; Interviews as Topic; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Treatment Refusal | 2003 |
Effects of an isopropanolic extract of Cimicifuga racemosa on urinary crosslinks and other parameters of bone quality in an ovariectomized rat model of osteoporosis.
Topics: 2-Propanol; Amino Acids; Animals; Bone and Bones; Bone Density; Cimicifuga; Female; Osteoporosis; Ovariectomy; Phytotherapy; Plant Extracts; Raloxifene Hydrochloride; Rats | 2003 |
[Evidence-based assessment of therapeutic agents of osteoporosis. Bisphosphonates, SERM and basic therapy in front].
Topics: Age Factors; Aged; Alendronate; Calcium; Cholecalciferol; Diphosphonates; Drug Therapy, Combination; Evidence-Based Medicine; Female; Humans; Male; Meta-Analysis as Topic; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Sex Factors | 2003 |
[Drugs prescription for osteoporosis].
Topics: Calcitonin; Dietary Supplements; Diphosphonates; Drug Utilization; Estrogen Replacement Therapy; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spain | 2003 |
New ways with old bones. Osteoporosis researchers look for drugs to replace hormone replacement therapy.
Topics: Antioxidants; Bone Resorption; Carrier Proteins; Contraindications; Female; Hormone Replacement Therapy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isoflavones; Leptin; Membrane Glycoproteins; Osteoporosis; Phytoestrogens; Plant Preparations; Raloxifene Hydrochloride; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Selective Estrogen Receptor Modulators; Teriparatide | 2004 |
Osteoporosis--diagnosis, treatment and management.
Topics: Aged; Calcitriol; Diphosphonates; Disease Progression; Evidence-Based Medicine; Female; Humans; Life Style; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors | 2004 |
Prevention of osteoporosis and osteoporotic fractures in postmenopausal women: recommendation statement from the Canadian Task Force on Preventive Health Care.
Topics: Aged; Bone Density; Diphosphonates; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Women's Health | 2004 |
Kynurenine and neopterin levels in patients with rheumatoid arthritis and osteoporosis during drug treatment.
Topics: Arthritis, Rheumatoid; Case-Control Studies; Etidronic Acid; Female; Humans; Kynurenine; Methotrexate; Neopterin; Osteoporosis; Prednisolone; Raloxifene Hydrochloride; Receptors, Glutamate; Tryptophan | 2003 |
Compliance with drug therapies for the treatment and prevention of osteoporosis.
Topics: Age Factors; Aged; Aged, 80 and over; Diphosphonates; Estrogen Replacement Therapy; Estrogens; Female; Fractures, Bone; Health Care Costs; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Osteoporosis; Patient Compliance; Raloxifene Hydrochloride; Retrospective Studies; Risk Factors | 2004 |
National trends in osteoporosis visits and osteoporosis treatment, 1988-2003.
Topics: Adult; Aged; Calcium; Diphosphonates; Drug Prescriptions; Estrogens; Female; Humans; Male; Middle Aged; Office Visits; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; United States | 2004 |
Safety profile of raloxifene as used in general practice in England: results of a prescription-event monitoring study.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Drug Interactions; England; Family Practice; Female; Flushing; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures | 2005 |
Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Breast Neoplasms; Computer Simulation; Cost-Benefit Analysis; Female; Humans; Middle Aged; Models, Economic; Osteoporosis; Quality-Adjusted Life Years; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Spinal Fractures; Sweden; Treatment Outcome | 2004 |
[Update 2004. Osteoporosis--management--current status].
Topics: Aged; Aged, 80 and over; Alendronate; Calcium, Dietary; Cross-Sectional Studies; Etidronic Acid; Female; Fractures, Spontaneous; Germany; Health Surveys; Hip Fractures; Humans; Male; Middle Aged; Osteoporosis; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risedronic Acid; Spinal Fractures; Vitamin D | 2004 |
Effects of 17beta-estradiol, tamoxifen and raloxifene on the protein and mRNA expression of interleukin-6, transforming growth factor-beta1 and insulin-like growth factor-1 in primary human osteoblast cultures.
Topics: Aged; Antineoplastic Agents, Hormonal; Cell Culture Techniques; Estradiol; Estrogen Antagonists; Female; Humans; Insulin-Like Growth Factor I; Interleukin-6; Middle Aged; Osteoblasts; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; RNA, Messenger; Tamoxifen; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2004 |
[Raloxifene for the treatment of osteoporosis].
Topics: Female; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2005 |
New help for old bones.
Topics: Age Distribution; Aged; Alendronate; Calcitonin; Estrogen Replacement Therapy; Humans; Mass Screening; Nurse's Role; Osteoporosis; Patient Education as Topic; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; United States | 2005 |
Raloxifene and vitamin K2 combine to improve the femoral neck strength of ovariectomized rats.
Topics: Administration, Oral; Animals; Bone Density; Compressive Strength; Disease Models, Animal; Drug Therapy, Combination; Female; Femur Neck; Lumbar Vertebrae; Osteocalcin; Osteogenesis; Osteoporosis; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Vitamin K 2 | 2005 |
Differing patterns of antiresorptive pharmacotherapy in nursing facility residents and community dwellers.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Bone Resorption; Calcitonin; Cross-Sectional Studies; Demography; Diphosphonates; Female; Hormone Replacement Therapy; Humans; Nursing Homes; Osteoporosis; Raloxifene Hydrochloride; Residence Characteristics | 2005 |
Quantifying the indirect treatment effect via surrogate markers.
Topics: Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservation Agents; Collagen; Collagen Type I; Data Interpretation, Statistical; Fractures, Bone; Osteocalcin; Osteoporosis; Peptides; Proportional Hazards Models; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic | 2006 |
What can be done about bone loss and what are the current treatments for it?
Topics: Bone Density Conservation Agents; Contraindications; Humans; Male; Osteoporosis; Raloxifene Hydrochloride | 2005 |
Decision rule based multiplicity adjustment strategy.
Topics: Bone Density Conservation Agents; Clinical Trials as Topic; Data Interpretation, Statistical; Decision Support Techniques; Humans; Osteoporosis; Raloxifene Hydrochloride | 2005 |
Standardized bending and breaking test for the normal and osteoporotic metaphyseal tibias of the rat: effect of estradiol, testosterone, and raloxifene.
Topics: Androgens; Animals; Bone Density; Bone Density Conservation Agents; Densitometry; Estradiol; Female; Male; Osteoporosis; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Rats, Wistar; Stress, Mechanical; Testosterone; Tibia | 2006 |
[Bisphosphonate or Raloxifene?: which drug we can choose for osteoporotic patients?].
Topics: Bone and Bones; Bone Density; Bone Density Conservation Agents; Diphosphonates; Humans; Osteoporosis; Raloxifene Hydrochloride | 2006 |
Osteoporosis: a global assessment.
Topics: Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2006 |
Cost-effectiveness strategies to treat osteoporosis in elderly women.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Calcitonin; Cost Savings; Cost-Benefit Analysis; Diphosphonates; Female; Fractures, Bone; Humans; Osteoporosis; Parathyroid Hormone; Quality of Life; Raloxifene Hydrochloride; Treatment Outcome | 2006 |
[New therapeutic approaches to osteoporosis].
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Female; Fractures, Bone; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride | 2006 |
Effect of the Women's Health Initiative on osteoporosis therapy and expenditure in Medicaid.
Topics: Calcitonin; Calcium; Cost of Illness; Diphosphonates; Estrogen Replacement Therapy; Female; Humans; Medicaid; Osteoporosis; Raloxifene Hydrochloride; United States; Women's Health | 2006 |
Raloxifene prevails in STAR trial, may face easier road to acceptance than previous drugs.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cataract; Contraindications; Controlled Clinical Trials as Topic; Drug Approval; Estrogen Receptor Modulators; Female; Hot Flashes; Humans; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Tamoxifen; Thromboembolism; Treatment Outcome; United States; United States Food and Drug Administration; Uterine Neoplasms | 2006 |
Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Comorbidity; Etidronic Acid; Female; Humans; Male; Managed Care Programs; Middle Aged; Osteoporosis; Patient Compliance; Raloxifene Hydrochloride; Risedronic Acid | 2006 |
Osteoporosis treatment: raloxifene (Evista) and stroke mortality.
Topics: Aged; Bone Density Conservation Agents; Female; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Stroke | 2006 |
[The successful development of bisphosphonates in the therapy of osteoporosis].
Topics: Administration, Oral; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Diphosphonates; Estrogen Antagonists; Female; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Primary Prevention; Raloxifene Hydrochloride; Risk Reduction Behavior | 2006 |
Analysis of change patterns of microcomputed tomography 3-dimensional bone parameters as a high-throughput tool to evaluate antiosteoporotic effects of agents at an early stage of ovariectomy-induced osteoporosis in mice.
Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Disease Models, Animal; Early Diagnosis; Estradiol; Female; Femur; Imaging, Three-Dimensional; Mice; Osteogenesis; Osteoporosis; Ovariectomy; Parathyroid Hormone; Peptide Fragments; Raloxifene Hydrochloride; Rolipram; Tomography, X-Ray Computed | 2006 |
Quantifying the treatment effect explained by markers in the presence of measurement error.
Topics: Absorptiometry, Photon; Biomarkers; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Data Interpretation, Statistical; Fractures, Bone; Humans; Logistic Models; Osteoporosis; Raloxifene Hydrochloride; Treatment Outcome | 2007 |
Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Italy; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Risedronic Acid; Risk Factors; Vitamin D | 2006 |
Editorial: The SERM of my dreams.
Topics: Bone Density; Breast Neoplasms; Coronary Disease; Female; Humans; Osteoporosis; Premenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2006 |
[Osteoporosis priority: Reduce the number of fractures].
Topics: Absorptiometry, Photon; Age Factors; Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Femoral Fractures; Fractures, Bone; Humans; Male; Middle Aged; Organometallic Compounds; Osteoporosis; Osteoporosis, Postmenopausal; Prospective Studies; Raloxifene Hydrochloride; Risk Factors; Spinal Fractures; Teriparatide; Thiophenes; Time Factors | 2006 |
Beyond raloxifene for the prevention of osteoporosis and breast cancer.
Topics: Breast Neoplasms; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2007 |
An analysis of which anti-osteoporosis therapeutic regimen would improve compliance in a population of elderly adults.
Topics: Aged; Cohort Studies; Diphosphonates; Drug Administration Schedule; Fasting; Female; Humans; Male; Middle Aged; Organometallic Compounds; Osteoporosis; Patient Compliance; Patient Satisfaction; Posture; Raloxifene Hydrochloride; Registries; Single-Blind Method; Surveys and Questionnaires; Teriparatide; Thiophenes; Twins | 2007 |
Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance.
Topics: Aged; Aged, 80 and over; Alendronate; Attitude to Health; Bone Density; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Cross-Over Studies; Drug Administration Schedule; Etidronic Acid; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Patient Compliance; Proportional Hazards Models; Raloxifene Hydrochloride; Retrospective Studies; Risedronic Acid; Risk Assessment; Severity of Illness Index; Treatment Outcome; United States | 2007 |
The search for good compliance: economic aspects of a conveyed combination pharmaco-therapy, exemplified by an osteoporosis therapy.
Topics: Bone Density Conservation Agents; Calcium, Dietary; Chronic Disease; Cost-Benefit Analysis; Dietary Supplements; Diphosphonates; Drug Combinations; Drug Packaging; Female; Germany; Humans; Male; Models, Econometric; Osteoporosis; Patient Compliance; Physician-Patient Relations; Raloxifene Hydrochloride | 2008 |
Raloxifene examined for breast cancer prevention.
Topics: Anticarcinogenic Agents; Bone Density Conservation Agents; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2007 |
Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women.
Topics: Alendronate; Drug Administration Schedule; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis; Patient Compliance; Postmenopause; Prospective Studies; Raloxifene Hydrochloride; Risedronic Acid | 2007 |
Comparative effects of 17beta-estradiol, raloxifene and genistein on bone 3D microarchitecture and volumetric bone mineral density in the ovariectomized mice.
Topics: Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Disease Models, Animal; Drug Evaluation, Preclinical; Estradiol; Female; Genistein; Mice; Mice, Inbred C57BL; Osteoporosis; Ovariectomy; Raloxifene Hydrochloride; Receptors, Estrogen; X-Ray Microtomography | 2008 |
Selective estrogen receptor modulation influences atherosclerotic plaque composition in a rabbit menopause model.
Topics: Animals; Atherosclerosis; Chemokine CCL2; Cyclooxygenase 2; Disease Models, Animal; Female; Magnetic Resonance Imaging; Matrix Metalloproteinase 1; Menopause; Osteoporosis; Ovariectomy; Rabbits; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2008 |
Summaries for patients. Drug therapy for osteoporosis.
Topics: Administration, Inhalation; Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Male; New Jersey; Osteoporosis; Osteoporosis, Postmenopausal; Pennsylvania; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors | 2008 |
Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.
Topics: Administration, Inhalation; Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Male; New Jersey; Osteoporosis; Osteoporosis, Postmenopausal; Pennsylvania; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors | 2008 |
Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats.
Topics: Aging; Animals; Bone Density; Ethinyl Estradiol; Female; Lipids; Organ Size; Osteoporosis; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Tibia; Tomography, X-Ray Computed; Uterus | 1995 |
Osteoporosis drugs show early promise.
Topics: Bone Density; Estrogen Antagonists; Humans; Osteoporosis; Piperidines; Raloxifene Hydrochloride; Tamoxifen | 1997 |
Next generation of SERMs being seen in clinic.
Topics: Antineoplastic Agents, Hormonal; Bone Density; Breast Neoplasms; Clinical Trials, Phase III as Topic; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Humans; Osteoporosis; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen | 1997 |
Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone.
Topics: Animals; Bone and Bones; Bone Density; Cinnamates; Estradiol; Estrogen Antagonists; Estrogens; Female; Humans; Osteoporosis; Ovariectomy; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Stilbenes; Tamoxifen; Tumor Cells, Cultured; Uterus | 1997 |
[Raloxifene: a new molecule for the prevention of menopausal osteoporosis].
Topics: Adult; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Osteoporosis; Piperidines; Raloxifene Hydrochloride | 1998 |
Biological basis of anti-resorptive therapies for osteoporosis.
Topics: Aged; Alendronate; Bone Resorption; Calcitonin; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride | 1998 |
Prevention of corticosteroid-induced osteoporosis and fractures.
Topics: Adrenal Cortex Hormones; Bone Density; Calcitonin; Calcitriol; Calcium Channel Agonists; Estrogen Antagonists; Fractures, Bone; Hormone Replacement Therapy; Humans; Osteoporosis; Piperidines; Raloxifene Hydrochloride | 1999 |
Osteoporosis: protecting bone mass with fundamentals and drug therapy.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Calcitonin; Calcium; Decision Trees; Dietary Supplements; Estrogen Replacement Therapy; Estrogens; Exercise; Female; Humans; Male; Mass Screening; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Piperidines; Primary Health Care; Raloxifene Hydrochloride; Risk Factors; Smoking Cessation; Vitamin D | 1999 |
Raloxifene as a multifunctional medicine? Current trials will show whether it is effective in both osteoporosis and breast cancer.
Topics: Breast Neoplasms; Estrogen Antagonists; Female; Humans; Osteoporosis; Piperidines; Raloxifene Hydrochloride | 1999 |
Women gain ground with BreastCare. Program ensures screening, treatment for poor.
Topics: Adult; Arkansas; Breast Neoplasms; Clinical Trials as Topic; Costs and Cost Analysis; Double-Blind Method; Estrogen Antagonists; Female; Humans; Mammography; Mass Screening; Medical Indigency; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 1999 |
Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Bone and Bones; Breast Neoplasms; Cholesterol; Estrogen Antagonists; Female; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Organ Size; Osteoporosis; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Reference Values; Tamoxifen; Toremifene; Transplantation, Heterologous; Tumor Cells, Cultured; Uterus | 2000 |
Comparative effects of estrogen and raloxifene on B lymphopoiesis and bone loss induced by sex steroid deficiency in mice.
Topics: Androgens; Animals; B-Lymphocytes; Bone Marrow; Bone Remodeling; Bone Resorption; Estradiol; Estrogen Replacement Therapy; Estrogens; Female; Hematopoiesis; Humans; Lymphocyte Count; Male; Mice; Orchiectomy; Organ Size; Osteoporosis; Osteoporosis, Postmenopausal; Ovariectomy; Raloxifene Hydrochloride; Uterus | 2000 |
[Raloxifene, selective estrogen receptor modulator (SERM). Introduction and conclusion].
Topics: Female; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2000 |
Vertebroplasty: an opportunity to do something really good for patients.
Topics: Alendronate; Bone Cements; Calcitonin; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures | 2000 |
Antiestrogens specifically up-regulate bone morphogenetic protein-4 promoter activity in human osteoblastic cells.
Topics: Adenocarcinoma; Base Sequence; Bone Morphogenetic Protein 4; Bone Morphogenetic Proteins; Bone Neoplasms; Breast Neoplasms; Cells, Cultured; Dimerization; Drug Design; Endometrial Neoplasms; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Estrogens; Female; Gene Expression Regulation; Humans; Molecular Sequence Data; Neoplasms, Hormone-Dependent; Organ Specificity; Osteoblasts; Osteogenesis; Osteoporosis; Osteosarcoma; Postmenopause; Promoter Regions, Genetic; Raloxifene Hydrochloride; Receptors, Estrogen; Recombinant Fusion Proteins; Stimulation, Chemical; Transfection; Tumor Cells, Cultured | 2000 |
Estrogen and atherothrombosis.
Topics: Arteriosclerosis; Attitude of Health Personnel; Coronary Disease; Estrogen Antagonists; Estrogens; Female; Hormone Replacement Therapy; Humans; Osteoporosis; Raloxifene Hydrochloride | 2000 |
Meeting the evolving therapeutic needs of postmenopausal women.
Topics: Aged; Drug Therapy, Combination; Estrogen Antagonists; Estrogens; Female; Hormone Replacement Therapy; Humans; Medroxyprogesterone; Middle Aged; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome | 2000 |
Coronary heart disease in women.
Topics: Endometrium; Estrogens; Female; Hormone Replacement Therapy; Humans; Osteoporosis; Progestins; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2000 |
Managing menopause after breast cancer: balancing risks and benefits.
Topics: Adult; Alendronate; Antidepressive Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Calcitonin; Climacteric; Cohort Studies; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Follow-Up Studies; Heart Diseases; Humans; Menopause; Menopause, Premature; Neoplasm Recurrence, Local; Osteoporosis; Pregnancy; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors | 2001 |
Bone builders: preventing and treating osteoporosis.
Topics: Aged; Estrogen Replacement Therapy; Female; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride | 2001 |
Bone builders: the discoveries behind preventing and treating osteoporosis.
Topics: Aged; Calcium; Female; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride | 2001 |
Update in general internal medicine.
Topics: Breast Neoplasms; Humans; Osteoporosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2001 |
Patterns of physician-reported diagnoses for women receiving raloxifene prescriptions.
Topics: Aged; Breast Neoplasms; Climacteric; Drug Approval; Drug Labeling; Drug Utilization Review; Estrogen Antagonists; Female; Humans; Medicine; Menopause; Middle Aged; Osteoporosis; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Specialization; United States | 2001 |
[What do we think about selective estrogen receptor modulators?].
Topics: Age Factors; Breast Neoplasms; Clinical Trials as Topic; Cohort Studies; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Follow-Up Studies; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Placebos; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Sex Factors; Time Factors | 2001 |
For osteoporosis, are two antiresorptive drugs better than one?
Topics: Alendronate; Drug Therapy, Combination; Humans; Osteoporosis; Raloxifene Hydrochloride | 2002 |